

COVID-19 Seroprevalence Report

December 3, 2023

Report #39: October 2023 Survey

Summary

October 2023

October 1 – October 31, 2023 (n = 31,977)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay).
- Spike antibody concentrations tend to be higher among those positive for Nucleocapsid antibodies compared with those positive for Spike antibodies only.

- Seroprevalence (natural infection) in October was 81.62% (95% CI 81.19, 82.06), similar to September (80.12% (95% CI 79.68, 80.57)). There was a week-to-week variation over October from 81.95% (95% CI 81.09, 82.80) to 81.31% (95% CI 80.43, 82.19) to 82.09% (95% CI 81.19, 82.99) to 81.24% (95% CI 80.42, 82.05).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 91.79% (95% CI 90.90, 92.67) compared to other age groups.
- Also consistent with previous surveys, Black, Indigenous and Racialized groups have a higher seroprevalence rate (86.78% (95% CI 85.93, 87.62)) compared to White donors (80.15% (95% CI 79.65, 80.66)).

September 2023

September 1 – September 30, 2023 (n = 31,764)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay).
- Spike antibody concentrations tend to be higher among those positive for Nucleocapsid antibodies compared with those positive for Spike antibodies only.

- Seroprevalence (natural infection) in September was 80.12% (95% CI 79.68, 80.57), similar to August (79.03% (95% CI 78.58, 79.49)). There was a week-to-week variation over September from 79.44% (95% CI 78.53, 80.35) to 79.04% (95% CI 78.07, 80.02) to 80.86% (95% CI 79.97, 81.74) to 80.88% (95% CI 80.07, 81.69).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 90.25% (95% CI 89.29, 91.20) compared to other age groups.
- Also consistent with previous surveys, Black, Indigenous and Racialized groups have a higher seroprevalence rate (86.09% (95% CI 85.25, 86.94)) compared to White donors (78.42% (95% CI 77.89, 78.94)).

August 2023

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay).
- Spike antibody concentrations tend to be higher among those positive for Nucleocapsid antibodies compared with those positive for Spike antibodies only.

- Seroprevalence (natural infection) in August was 79.03% (95% CI 78.58, 79.49), similar to July (79.94% (95% CI 79.50, 80.39)). There was a week-to-week variation over August from 79.10% (95% CI 78.17, 80.03) to 79.10% (95% CI 78.16, 80.03) to 78.79% (95% CI 77.81, 79.77) to 79.10% (95% CI 78.28, 79.91).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 87.87% (95% CI 86.83, 88.91) compared to other age groups.
- Also consistent with previous surveys, Black, Indigenous and Racialized groups have a higher seroprevalence rate (84.52% (95% CI 83.65, 85.39)) compared to White donors (77.28% (95% CI 76.75, 77.82)).

July 2023

July 1 – July 31, 2023 (n = 31,978)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay).
- Spike antibody concentrations tend to be higher among those positive for Nucleocapsid antibodies compared with those positive for Spike antibodies only.

- Seroprevalence (natural infection) in July was 79.94% (95% CI 79.50, 80.39), similar to June (80.00% (95% CI 79.55, 80.44 p = 0.87)). There was a week-to-week variation over July from 78.92% (95% CI 77.96, 79.88) to 79.60% (95% CI 78.69, 80.50) to 79.94% (95% CI 79.01, 80.87) to 80.98% (95% CI 80.18, 81.77).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 90.00% (95% CI 89.05, 90.96) compared to other age groups.
- Also consistent with previous surveys, Black, Indigenous and Racialized groups have a higher seroprevalence rate (84.72% (95% CI 83.87, 85.58)) compared to White donors (78.40% (95% CI 77.88, 78.93)).

June 1 – June 30, 2023 (n = 31,790)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay).
- Spike antibody concentrations tend to be higher among those positive for Nucleocapsid antibodies compared with those positive for Spike antibodies only.

- Seroprevalence (natural infection) in June was 80.00% (95% CI 79.55, 80.44), similar to May (79.64% (95% CI 79.19, 80.09 p = 0.27)). There was a week-to-week variation over June from 80.24% (95% CI 79.31, 81.16) to 80.93% (95% CI 80.03, 81.82) to 79.11% (95% CI 78.17, 80.04) to 79.76% (95% CI 78.94, 80.58).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 90.22% (95% CI 89.27, 91.17) compared to other age groups.
- Also consistent with previous surveys, Black, Indigenous and Racialized groups have a higher seroprevalence rate (85.65% (95% CI 84.78, 86.52)) compared to White donors (78.38% (95% CI 77.86, 78.90)).

May 2023

May 1 – May 31, 2023 (n = 31,711)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay).
- Spike antibody concentrations tend to be higher among those positive for Nucleocapsid antibodies compared with those positive for Spike antibodies only.

- Seroprevalence (natural infection) in May was 79.64% (95% CI 79.19, 80.09), similar to April (79.41% (95% CI 78.96, 79.86) p = 0.48)). There was a week-to-week variation over May from 79.89% (95% CI 78.97, 80.80) to 78.63% (95% CI 77.69, 79.57) to 80.17% (95% CI 79.23, 81.11) to 79.85% (95% CI 79.03, 80.66).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 89.89% (95% CI 88.92, 90.85) compared to other age groups.
- Also consistent with previous surveys, Black, Indigenous and Racialized groups have a higher seroprevalence rate (84.68% (95% CI 83.79, 85.57)) compared to White donors (78.07% (95% CI 77.54, 78.59)).

April 2023

April 1 – April 30, 2023 (n = 31,979)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay).
- Spike antibody concentrations tend to be higher among those positive for Nucleocapsid antibodies, compared with those positive for Spike antibodies only.

- Seroprevalence (natural infection) in April was 79.41% (95% CI 78.96, 79.86) only slightly higher than in March (78.67% (95% CI 78.21, 79.13) p = 0.02). There was a week-to-week variation over April from 78.88% (95% CI 77.91, 79.84) to 78.72% (95% CI 77.77, 79.67) to 79.86% (95% CI 78.97, 80.75) to 79.97% (95% CI 79.15, 80.78).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 89.42% (95% CI 88.44, 90.41) compared to other age groups.
- Also consistent with previous surveys, Black, Indigenous and Racialized groups have a higher seroprevalence rate (83.95% (95% CI 83.02, 84.88)) compared to White donors (78.21% (95% CI 77.69, 78.73)).

March 2023

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay).
- Spike antibody concentrations tend to be higher among those positive for Nucleocapsid antibodies, compared with those positive for Spike antibodies only.

- Seroprevalence (natural infection) in March was 78.67% (95% CI 78.21, 79.13), only slightly higher than in February (77.59%, 95% CI 77.13, 78.06), P 0.0013). There was a week-to-week variation over March from 77.96% (95% CI 76.88, 79.03) to 78.41% (95% CI 77.49, 79.32) to 79.41% (95% CI 78.42, 80.40) to 78.71% (95% CI 77.92, 79.50).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 89.17% (95% CI 88.17, 90.18) compared to other age groups.
- Also consistent with previous surveys, Black, Indigenous and Racialized groups have a higher seroprevalence rate (84.33% (95% CI 83.38, 85.27)) compared to White donors (77.17% (95% CI 76.63, 77.71)).

February 2023

February 1 – February 28, 2023 (n = 31,755)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay). This was largely driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration. Recently rising values in most age groups may be related to vaccination or infection. February 2023 saw a slight decrease in concentrations among older age groups.

- Seroprevalence (natural infection) in February was 77.59% (95% CI 77.13, 78.06), higher than in January (76.73%, 95% CI 76.27, 77.20), P < 0.01). There was a week-to-week variation over February from 78.48% (95% CI 77.56, 79.40) to 77.22% (95% CI 76.26, 78.19) to 77.01% (95% CI 76.08, 77.93) to 77.49% (95% CI 76.62, 78.37).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 88.40% (95% CI 87.38, 89.42) compared to other age groups. The seroprevalence rate increased in 17-24 and 40-59 age groups compared to January.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (83.52% (95% CI 82.60, 84.44)) compared to White donors (75.92% (95% CI 75.38, 76.46)).

January 2023

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay). This was largely driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration. Recently rising values in most age groups may be related to vaccination or infection. January 2023 saw a slight decrease in concentrations among older age groups.

- Seroprevalence (natural infection) in January was 76.72% (95% CI 76.25, 77.19), higher than in December (73.50%, 95% CI 73.01, 73.98), P < 0.0001). There was a gradual week-to-week change over January from 76.08% (95% CI 75.14, 77.03) to 75.91% (95% CI 74.97, 76.85) to 76.46% (95% CI 75.59, 77.34) to 78.48% (95% CI 77.54, 79.43).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 86.55% (95% CI 85.46, 87.63) compared to other age groups. The seroprevalence rate increased in all age groups, excluding 17-24 year olds, compared to December.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (81.95% (95% CI 80.97, 82.94)) compared to White donors (75.44% (95% CI 74.91, 75.98)).

December 2022 December 1 – December 31, 2022 (n = 32,698)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration. Recently rising values in most age groups may be related to vaccination or infection.

- Seroprevalence (natural infection) in December was 73.50% (95% CI 73.01, 73.98), higher than in November was 70.78% (95% CI 70.27, 71.30), P < 0.0001). There was a gradual week-to-week increase over December from 71.6% (95% CI 70.52, 72.69) to 73.04% (95% CI 72.19, 73.90) to 73.82% (95% CI 72.88, 74.76) to 75.26% (95% CI 74.27, 76.22).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 86.76% (95% CI 85.70, 87.82) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to November.
- Seroprevalence rates increased in December compared to November in all provinces, however the increase was not statistically significant in Nova Scotia and Prince Edward Island.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (79.57% (95% CI 78.56, 80.58)) compared to White donors (71.97% (95% CI 71.41, 72.52)).

November 2022 November 1 – November 30, 2022 (n = 31,080)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration. Recently rising values in most age groups may be related to vaccination or infection.

- Seroprevalence (natural infection) in November was 70.78% (95% CI 70.27, 71.30), higher than in October was 67.37% (95% CI 66.84, 67.89), P < 0.0001). There was week-to-week fluctuation over November from 69.90% (95% CI 68.74, 71.06) to 70.42% (95% CI 69.50, 71.34) to 71.23% (95% CI 70.26, 72.20) to 70.80% (95% CI 69.77, 71.83).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 84.55% (95% CI 83.39, 85.71) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to October.
- Seroprevalence rates increased in November compared to October in all provinces, however the increase was not statistically significant in Saskatchewan, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (78.67% (95% CI 77.65, 79.70)) compared to White donors (68.58% (95% CI 67.99, 69.17)).

October 2022 October 1 – October 31, 2022 (n = 31,457)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration. Recently rising values in most age groups may be related to vaccination or infection.

- Seroprevalence (natural infection) in October was 67.37% (95% CI 66.84, 67.89), higher than in September (63.22% (95% CI 62.69, 63.76), P < 0.0001). There was a modest week to-week change over October from 66.37% (95% CI 65.29, 67.44) to 66.12% (95% CI 65.07, 67.16) to 67.79% (95% CI 66.72, 68.86) to 68.47% (95% CI 67.51, 69.42).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate at 81.73% (95% CI 80.50, 82.96) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to September.
- Seroprevalence rates increased in October compared to September in all provinces, however the increase was not statistically significant in Manitoba, New Brunswick, Prince Edward Island and Newfoundland.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (75.25% (95% CI 74.14, 76.35)) compared to White donors (65.33% (95% CI 64.73, 65.94)).

September 2022 September 1 – September 30, 2022 (n = 31,637)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration.

- Seroprevalence (natural infection) in September was 63.22% (95% CI 62.69, 63.76), higher than in August (58.54% (95% CI 58.02, 59.06)), *P* < 0.0001). There was a modest week-to-week change over September from 61.14% (95% CI 60.02, 62.26) to 63.43% (95% CI 62.41, 64.46) to 62.85% (95% CI 61.84, 63.86) to 65.38% (95% CI 64.29, 66.48).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (78.26% (95% CI 76.96, 79.57) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to August.
- Seroprevalence rates increased in September compared to August in all provinces, however the increase was not statistically significant in Newfoundland and Prince Edward Island.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (70.14% (95% CI 68.97, 71.31)) compared to White donors (61.75% (95% CI 61.13, 62.37)).

August 2022

August 1 – August 31, 2022 (n = 35,165)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration.

- Seroprevalence (natural infection) in August was 58.54% (95% CI 58.02, 59.06), higher than in July (54.01% (95% CI 53.45, 54.56)), *P* < 0.0001). There was a modest week-to-week change over August from 56.80% (95% CI 55.64, 57.96) to 58.29% (95% CI 57.30, 59.27) to 58.59% (95% CI 57.59, 59.59) to 59.87% (95% CI 58.89, 60.86).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (74.98% (95% CI 73.68, 76.28) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to July.
- Seroprevalence rates increased in August compared to July in all provinces, however the increase was not statistically significant in Saskatchewan and Prince Edward Island.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (67.44% (95% CI 66.30, 68.58)) compared to White donors (56.62% (95% CI 56.02, 57.23)).

July 2022

July 1 – July 31, 2022 (n = 31,275)

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration. A slight increase in concentration in those over 60 was observed in May and June, consistent with a fourth dose, however this increase levelled off in July.

- Seroprevalence (natural infection) in July was 54.01% (95% CI 53.45, 54.56), higher than in June (50.7% (95% CI 50.15, 51.26)) *P* < 0.0001). There was a modest week-to-week change over July from 52.32% (95% CI 51.22, 53.42) to 52.70% (95% CI 51.62, 53.77) to 54.68% (95% CI 53.61, 55.74) to 56.51% (95% CI 55.35, 57.67).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (71.15% (95% CI 69.71, 72.59) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to June.
- Seroprevalence rates increased in July compared to June in all provinces except PEI, however the increase was only statistically significant in British Columbia, Ontario, New Brunswick and Newfoundland.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (62.27% (95% CI 61.03, 63.51)) compared to White donors (52.01% (95% CI 51.37, 52.06)).

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration. An increase in concentration in those over 60 is observed in May and contunued into June consistent with a fourth dose.

- Seroprevalence (natural infection) in June was 50.7% (95% CI 50.15, 51.26), higher than in May 2022 (46.32% (95% CI 45.77, 46.87) *P* < 0.0001). There was minimal week-to-week change over June from 50.47% (95% CI 49.32, 51.63) to 51.07% (95% CI 50.04, 52.10) to 50.26% (95% CI 49.25, 51.27) to 50.76% (95% CI 49.58, 51.94).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (66.29% (95% CI 64.81, 67.77) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to May.
- Seroprevalence rates increased in June compared to May in all provinces.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (58.03% (95% CI 56.79, 59.27)) compared to White donors (49.01% (95% CI 48.38, 49.65)).

May 2022

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 100.00% (95% CI 100.00, 100.00%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration. An increase in concentration in those over 60 is observed in May.

- Seroprevalence (natural infection) in May 2022 was 46.32% (95% CI 45.77, 46.87), higher than April 2022 (36.71% (95% CI 36.16, 37.26), *P* < 0.0001). There was a gradual increase over May from 42.74% (95% CI 41.65, 43.84) to 46.11% (95% CI 45.00, 47.21) to 47.03% (95% CI 45.96, 48.10) to 48.96% (95% CI 47.87, 50.06) with the persistence of the Omicron variant.
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (64.47% (95% CI 62.96, 65.98) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to April.
- Seroprevalence rates increased in May compared to April in all provinces except PEI.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (54.35% (95% CI 53.12, 55.58)) compared to White donors (44.31% (95% CI 43.67, 44.95)).
- Among repeat tested donors, new infections in unvaccinated donors have increased from June 2021 1.53% (95% CI 1.14, 2.00) to 9.12% (95% CI 8.24, 10.07) in January 2022 and 46.83% (95% CI 44.57, 49.10) in May 2022
- Potential breakthrough infections remained low from June 2021 to December 2021, but increased from 5.19% (95% CI 4.68, 5.74) in January 2022 to 31.02% (95% CI 30.17, 31.88) in May 2022.

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 99.74% (95% CI 99.60, 99.88%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September 2021, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February 2022 likely due to third vaccine dose administration, but are now declining.

- Seroprevalence (natural infection) in April 2022 was 36.71% (95% CI 36.16, 37.26), higher than March 2022 (28.70% (95% CI 28.15, 29.26), *P* < 0.0001). There was a gradual increase over April from 32.83% (95% CI 31.67, 33.98) to 35.54% (95% CI 34.47, 36.60) to 37.64% (95% CI 36.62, 38.65) to 40.04% (95% CI 38.90, 41.18) with the persistence of the Omicron variant.
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (55.37% (95% CI 53.76, 56.99) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to March.
- Seroprevalence rates increased in April compared to March in all provinces.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (45.06% (95% CI 43.77, 46.34)) compared to White donors (34.78% (95% CI 34.15, 35.42)).
- Among repeat tested donors, new infections in unvaccinated donors have increased from June 2021 1.53% (95% CI 1.14, 2.00) to 9.12% (95% CI 8.24, 10.07) in January 2022 and 37.19% (95% CI 35.14, 39.28) in April 2022
- Potential breakthrough infections remained low from June 2021 to December 2021, but increased from 5.19% (95% CI 4.68, 5.74) in January 2022 to 21.99 (95% CI 21.19. 22.80) in April 2022.

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 99.57% (95% CI 99.42, 99.73%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February likely due to third vaccine dose administration, but were starting to decline in March.

- Seroprevalence (natural infection) in March 2022 was 28.70% (95% CI 28.15, 29.25), higher than February 2022 (23.68% (95% CI 23.18, 24.18).(*P* < 0.0001). There was a gradual increase over the 31 day reporting period from 27.02% (95% CI 25.95, 28.09) to 27.54% (95% CI 26.47, 28.61) to 30.68% (95% CI 29.61, 31.75) to 29.52% (95% CI 28.34, 30.69) consistent with the persistence of the Omicron variant.
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (44.27% (95% CI 42.54, 46.01) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to February.
- Seroprevalence rates increased in March compared to February in all provinces with the exception of Prince Edward Island and Newfoundland and Labrador where sample sizes are smaller.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (38.58% (95% CI 37.21, 39.95)) compared to White donors (26.27% (95% CI 25.65, 26.89)).
- Among repeat tested donors, new infections in unvaccinated donors have increased from June 1.53% (95% CI 1.14, 2.00) to 9.12% (95% CI 8.24, 10.07) in January and 29.49% (95% CI 27.57, 31.48) in March
- Potential breakthrough infections remained low from June to December, but increased from 5.19% (95% CI 4.68, 5.74) in January to 17.50 (95% CI 16.66, 18.37) in March.

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 99.60% (95% CI 99.45, 99.75%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by February likely due to third vaccine dose administration.

- Seroprevalence (natural infection) in February 2022 was 23.68% (95% CI 23.18, 24.18), higher than January 2022 (12.12% (95% CI 11.76, 12.48).(*P* < 0.0001). There was a gradual increase over the 28 day reporting period from 21.39% (20.31, 22.48) to 23.43% (22.41, 24.45) to 23.68% (22.77, 24.58) to 25.25% (95% CI 24.30, 26.20) consistent with emergence of the Omicron variant.
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (36.27% (95% CI 34.68, 37.86%)) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to January.
- Seroprevalence rates increased in February compared to January in all provinces.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (33.45% (95% CI 32.16, 34.73)) compared to White donors (21.17% (95% CI 20.62, 21.72%)).
- Among repeat tested donors, new infections in unvaccinated donors have increased from June 1.53% (1.14, 2.00) to 9.12% (95% CI 8.24, 10.07) in January, and more than doubled in February (23.71%, 95% CI 22.10, 25.37).
- Potential breakthrough infections remained low from June to December, but increased from 5.19% (95% C I4.68, 5.74) in January to 15.56% (95% CI 14.72, 16.42) in February.

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was 98.89% (95% CI 98.73, 99.06%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September, but gradually decreased. A peak in values followed by decline is expected after vaccination. Concentrations increased in all age groups by January likely due to third vaccine dose administration.

- Seroprevalence (natural infection) in January 2022 was 12.12% (95% CI 11.76, 12.48), higher than December 2021 at 6.39% (95% CI 6.01, 6.76) (*P* < 0.001). There was a gradual increase over the 31 day reporting period from 7.16% (6.62, 7.71) to 10.09% (9.46, 10.71) to 12.65% (11.84, 13.45) to 16.30% (95% CI 15.51, 17.09) consistent with emergence of the Omicron variant.
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (22.22% (95% CI 20.93, 23.51%)) compared to other age groups. However, the seroprevalence rate increased in all age groups compared to December.
- Seroprevalence rates increased in January compared to December in almost all provinces.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (18.29% (95% CI 17.27, 19.32)) compared to White donors (10.73% (95% CI 10.34, 11.12%)).
- Among repeat tested donors, new infections in unvaccinated donors have increased from June 1.53% (1.14, 2.00) to 3.91% (3.11, 4.83%) in December and more than doubled in January to 9.012% (95% CI 8.24, 10.07).
- Potential breakthrough infections remained low from June to December, but increased from 0.74% (95% CI 0.48, 1.10) in December to 5.19% (95% CI 4.68, 5.74) in January.

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 98.58% (95% CI 98.34, 98.82%) (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were high by September, but gradually decreased. A peak in values followed by decline is expected after vaccination. By December, concentrations increased in older age groups likely due to administration of third doses consistent with policies to vaccinate older age groups earlier.

- Seroprevalence (natural infection) in December was 6.39% (95% CI 6.01, 6.76), higher than November at 5.08% (95% CI 4.58, 5.50) (*P* < 0.001). There was a gradual increase over the 17 day reporting period from 5.60% (5.03, 6.18) to 6.55% (5.95, 7.15) to 7.51% (6.63, 8.39) consistent with emergence of the Omicron variant.
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (11.37% (95% CI 9.99, 12.75%)) compared to other age groups.
- Seroprevalence rates remained similar to November in most provinces, however, rates increased in December in Alberta (12.94% (95% CI 11.62, 14.27%), P < 0.001) and Ontario (5.43% (95% CI 4.94, 5.92%), P < 0.001) compared to November.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (10.40% (95% CI 9.32, 11.48%)) compared to White donors (5.21% (95% CI 4.81, 5.61%)).
- Among repeat tested donors, new infections in unvaccinated donors have increased since June 1.53% (1.14, 2.00) to 3.91% (3.11, 4.83%) in December but vaccine breakthrough infections are low, 0.74% (0.48, 1.10%).

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The (adjusted) proportion of blood donors with humoral immunity for SARS-CoV-2 was was 98.52% (95% CI 98.18, 98.86%), slightly higher than October (based on results from the Spike antibody assay)(*P* = 0.039). This was predominantly driven by vaccination.
- Spike antibody concentrations were very high (>2500 U/mL) by July, but gradually
 decreasing in almost all age groups as the months progress with the greatest
 decrease in older age groups. A peak in values followed by decline is expected after
 vaccination. These results are consistent with policies to vaccinate older age groups
 earlier.

- Seroprevalence (natural infection) in November was 5.08% (95% CI 4.58, 5.50), higher than October at 4.26% (95% CI 3.85, 4.68%) (*P* = 0.014).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (9.35% (95% CI 7.62, 11.07%)) compared to other age groups.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (8.28% (95% CI 6.82, 9.74%)) compared to White donors (4.56% (95% CI 4.05, 5.07%)).
- Among repeat tested donors, new infections in unvaccinated donors have increased since June 1.53% (1.14, 2.00) to 3.19% (2.42, 4.13) in November but vaccine breakthrough infections are low, 0.6% (0.37, 0.93).

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The proportion of blood donors with humoral immunity for SARS-CoV-2 was 98.01% (95% CI 97.65, 98.36%), slightly higher than September (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were very high (>2500 AU/mL) by July, but began to decrease in older individuals by September. In October values are still very high but gradually decreasing in all age groups. A peak in values followed by decline is expected after vaccination. These results are consistent with policies to vaccinate older age groups earlier.
- Similar to past reports, donors living in affluent neighbourhoods had higher seroprevalence rates, 99.25% (95% CI 98.72, 99.79%) compared to those living in the most materially deprived neighbourhoods, 97.13% (95% CI 95.64, 98.61%).
- Of 25,100 donors tested on 2 or more occasions since January 2021, the most common (55.2%) test profile was presumed unvaccinated to vaccinated (N negative S negative on their first tested donation and N negative S positive on their last tested donation). There were 15 presumed breakthrough infections (donors who were N negative S positive on their first tested donation and N positive S positive on their last tested donation).

- Seroprevalence (natural infection) in October was 4.26% (95% CI 3.85, 4.68%) similar to September, 2021 at 4.38% (95% CI 3.96, 4.81%).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (7.50% (95% CI 5.98, 9.01%) compared to other age groups.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (6.18% (95% CI 4.92, 7.45%)) compared to White donors (3.85% (95% CI 3.40, 4.31%)).

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The proportion of blood donors with humoral immunity for SARS-CoV-2 was 97.03% (95% CI 96.62, 97.44%), slightly higher than August (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Spike antibody concentrations were very high (>2500 AU/mL) by July, but are beginning to decrease in older individuals by September. A peak in values followed by decline is expected after vaccination. These results are consistent with policies to vaccinate older age groups earlier.
- Similar to past reports, donors living in affluent neighbourhoods had higher seroprevalence rates, 97.56% (95% CI 96.83, 98.28%) compared to those living in the most materially deprived neighbourhoods, 94.72% (95% CI 92.93, 96.51%).
- Of 21,727 donors tested on 2 or more occasions since January 2021, the most common (54.0%) test profile was presumed unvaccinated to vaccinated (N negative S negative on their first tested donation and N negative S positive on their last tested donation). There were 12 presumed breakthrough infections (donors who were N negative S positive on their first tested donation and N positive S positive on their last tested donation).

- Seroprevalence (natural infection) in September was 4.38% (95% CI 3.96, 4.81%) similar to August, 2021 at 4.43% (95% CI 3.99, 4.86%).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (8.70% (95% CI 7.06, 10.34%) compared to other age groups. Rates in the 60+ age group increased significantly in September (2.78% (95% CI 2.13, 3.43%)) compared to August (1.61% (95% CI 1.09, 2.12%)) while other age groups did not change.
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (7.61% (95% CI 6.24, 8.97%)) compared to White donors (3.65% (95% CI 3.20, 4.10%)).

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The proportion of blood donors with humoral immunity for SARS-CoV-2 was 96.09% (95% CI 95.63, 96.54) slightly up from July (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Median spike antibody concentrations increased in July compared to previous months (P < 0.001) but increased even further in August (P < 0.001).
- Similar to past reports, donors living in affluent neighbourhoods had higher seroprevalence rates, 98.25% (95% CI 97.56, 98.95%) compared to those living in the most materially deprived neighbourhoods, 93.41% (95% CI 91.45, 95.37%).
- Of 17,762 donors tested on 2 or more occasions since January 2021, the most common (52.9%) test profile was presumed unvaccinated to vaccinated (N negative S negative on their first tested donation and N negative S positive on their last tested donation). There were 11 presumed breakthrough infections (donors who were N negative S positive on their first tested donation and N positive S positive on their last tested donation).

- Seroprevalence (natural infection) in August was 4.43% (95% CI 3.99, 4.86%) similar to July, 2021 at 4.08% (95% CI 3.65, 4.51%).
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (8.44% (95% CI 6.80, 10.09%) compared to other age groups. Rates in this age group were highest in Manitoba at 24.95% (95% CI 13.53, 36.37%).
- Black, Indigenous and Racialized groups have a higher seroprevalence rate (11.14% (95% CI 9.14, 13.15%)) compared to White donors (3.30% (95% CI 2.86, 3.74%)). Natural infection rates in Black, Indigenous and Racialized donors also increased significantly compared to July. Compared to previous reports, the gap between those in materially deprived vs. affluent neighbourhoods has begun to widen likely due to the 4th wave, 7.85% (95% CI 5.87, 9.83%) vs 3.27% (95% CI 2.52, 4.02%).

July 2021

Humoral Immunity (Based on results from the Spike antibody assay):

- Spike antibody results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Nucleocapsid and Spike antibody positive results together likely have been infected and may or may not have been vaccinated.
- The proportion of blood donors with humoral immunity for SARS-CoV-2 was 94.69% (95% CI 94.16, 95.22) a significant increase from June (based on results from the Spike antibody assay). This was predominantly driven by vaccination.
- Median Spike antibody concentrations increased in June compared to previous months (*P* < 0.001) but increased more in July (*P* < 0.001).
- The seroprevalence of White donors (95.04% (95% CI 94.44, 95.64%) was not different from Black, Indigenous and Racialized groups (93.82% (95% CI 92.48, 95.15%)), this gap has closed compared to earlier surveys. Similar to past reports, donors living in affluent neighbourhoods had higher seroprevalence rates, 96.72% (95% CI 95.82, 97.61%) compared to those living in the most materially deprived neighbourhoods, 92.94% (95% CI 90.89, 95.00%).
- Of 14, 201 donors tested on 2 or more occasions since January 2021 the most common (51.2%) test profile was N negative S negative on their first tested donation and N negative S positive on their last tested donation, most likely due to vaccination. There were 5 donors who were N negative S positive on their first tested donation and N positive S positive on their last tested donation, potentially breakthrough infections.

- Seroprevalence (natural infection) in July was 4.08% (95% CI 3.65, 4.51%), decreased from June, 2021.
- Natural seroprevalence in most provinces except Alberta plateaued, likely due to widescale vaccination and social restrictions.
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (6.71% (95% CI 5.17, 8.25%)) compared to other age groups, however, this number has decreased since June, 2021.
- Rates in this age group were highest in Alberta at 11.88% (95% CI 6.80, 16.97%) and British Columbia at 9.91% (95% CI 5.44, 14.37%). Since June, 2021 these rates have decreased or stayed very similar in almost every province with the exception of British Columbia where they have increased.
- Black, Indigneous and Racialized groups had a higher seroprevalence rate (7.29% (95% CI 5.95, 8.63%)) compared to White donors (3.33% (95% CI 2.87, 3.78%)). Compared to previous reports, the gap between those in materially deprived vs. affluent neighbourhoods is closing, 4.62% (95% CI 3.03, 6.22%) vs 3.87% (95% CI 3.02, 4.71%). However, those living in more socially deprived settings (had lower social contact) had lower seroprevalence rates compared to those that were least deprived, 3.35% (95% CI 2.39, 4.30%) vs. 5.63% (95% CI 4.47, 6.80%).

June 2021

June 14 – June 29, 2021 (n = 16,884)

Humoral Immunity (Based on results from the Roche S assay):

- Roche S results indicate a SARS-CoV-2 humoral response to vaccination or natural infection. Because people are advised to be vaccinated irrespective of past infection, those with Roche N and S positive results together likely have been infected and may or may not have been vaccinated.
- The proportion of blood donors with humoral immunity for SARS-CoV-2 was 90.78% (95% CI 90.32, 91.25) a significant increase from May (based on results from the Roche S assay). This was predominantly driven by vaccination.
- The proportion of blood donors with presumed vaccine-induced humoral immunity to SARS-CoV-2 was 86.05% (95% CI 85.50, 86.59%), a significant increase from May (based on results from the Roche S-only assay).
- White donors did not have different seroprevalence rates (Roche S, primarily vaccine-induced) (90.81% (95% CI 90.25, 91.35%) compared to Black, Indigenous and Racialized groups (91.37% (95% CI 90.27, 92.47%)), this gap has closed compared to previous surveys. However, White donors had higher seroprevalence rates (Roche S-only, presumed vaccine induced) (86.87% (95% CI 86.26, 87.49%)), compared to Black, Indigenous and Racialized groups (83.14% (95% CI 81.72, 84.56%)) with a decreased difference between these two groups compared to May. Similarly, donors living in affluent neighbourhoods had higher seroprevalence rates (Roche S, primarily vaccine-induced), 93.68% (95% CI 92.90, 94.46%) compared to those living in the most materially deprived neighbourhoods, 88.33% (95% CI 86.60, 90.06%).

Natural Infections (Based on results from the Roche N assay):

- Seroprevalence (natural infection) in June was 4.5% (95% CI 4.19, 4.83%), increased from May, 2021.
- Natural infections in most provinces except Alberta plateaued, likely due to widescale vaccination.
- Consistent with previous surveys, donors aged 17-24 years old had the highest seroprevalence rate (9.3% (95% CI 8.04, 10.57%)) compared to other age groups.
- Rates in this age group were highest in Alberta at 17.53% (95% CI 13.23, 21.82%), Saskatchewan at 14.26% (95% CI 6.66, 21.87%), and Manitoba at 15.56% (95% CI 8.46, 22.65%).
- Black, Indigenous and Racialized groups had a higher seroprevalence rate (7.95% (95% CI 6.95, 8.95%)) compared to White donors (3.72% (95% CI 3.38, 4.06%)). Those living in materially deprived vs. affluent neighbourhoods had a higher rate of natural infections, 6.95% (95% CI 5.62, 8.27%) vs 4.26% (95% CI 3.66, 4.87%).

May 2021

 The proportion of blood donors with humoral immunity for SARS-CoV-2 was 63.9% (95% CI 63.2, 64.6) a significant increase from April (based on results from the Roche S assay). This was predominantly driven by vaccination.

Vaccine-Induced Humoral Immunity (Reactive to Roche S-only):

- The proportion of blood donors with vaccine-induced humoral immunity to SARS-CoV-2 was 59.8% (95% 59.1, 60.6), a significant increase from April.
- White donors had higher seroprevalence rates (vaccine-induced) (61.8% (95% CI 60.9, 62.7) compared to Black, Indigenous and Racialized groups (48.9% (95% CI 47.1, 50.7%). Similarly, donors living in affluent neighbourhoods also had higher seroprevalence rates 64.8% (95% CI 63.4, 66.2%) compared to those living in the most materially deprived neighbourhoods, 56.6% (95% CI 54.0, 59.1%).

Natural Infections (Based on results from the Roche N assay):

- Seroprevalence (natural infection) in May was 4.0% (95% CI 3.7, 4.3), increased from April, 2021.
- Natural infections in most provinces except Ontario and Alberta plateaued, likely due to widescale vaccination.
- Consistent with previous surveys donors aged 17-24 years old had the highest seroprevalence rate (7.0% (95% CI 5.9, 8.1)) compared to other age groups.
- Rates in this age group were highest in Alberta 12.7% (95% CI 9.0, 16.4) and Manitoba 11.3% (95% CI 5.2, 17.4).
- Black, Indigenous and Racialized groups had a higher seroprevalence rate (7.4% (95% CI 6.5, 8.3)) compared to White donors (3.3% (95% CI 2.9, 3.6)). Those living in materially deprived vs. affluent neighbourhoods had a higher rate of natural infections 5.7% (95% CI 4.5, 6.8) vs 3.1% (95% CI 2.6, 3.6).

April 2021

April 13 – April 30, 2021 (n = 16,931)

The proportion of blood donors with humoral immunity to SARS-CoV-2 was 26.9% (95% CI 26.2, 27.6) a significant increase from March (based on results from the Roche S assay). This was predominantly driven by vaccination.

Vaccine-Induced Humoral Immunity (Reactive to Roche S-only):

- The proportion of blood donors with vaccine-induced humoral immunity to SARS-CoV-2 was 23.6% (95% 23.0, 24.3), a significant increase from March.
- Vaccine inequity emerged in April 2021.
- White donors had higher seroprevalence rates (vaccine-induced) (25.0% (95% CI 24.3, 25.8) compared to Black, Indigenous and Racialized groups (17.9% (95% CI 16.5, 19.3%). Similarly, donors living in affluent neighbourhoods also had higher seroprevalence rates 26.9% (95% CI 25.6, 28.2%) compared to those living in the most materially deprived neighbourhoods, 20.9% (95% CI 18.8, 23.0%).

Natural Infections (Based on results from the Roche N assay):

- Seroprevalence (natural infection) in April was 3.2% (95% CI 3.0, 3.5), similar to March 2021.
- Natural infections in most provinces except Ontario decreased or plateaued, likely due to widescale vaccination.
- Consistent with previous surveys donors aged 17-24 years old had the highest seroprevalence rate (5.4% (95% CI 4.4, 6.3)) compared to other age groups.
- Rates in this age group were significantly higher in Alberta 8.9% (95% CI 5.7, 12.0) and Manitoba 15.0% (95% CI 7.9, 22.0) compared to the full sample.
- Black, Indigenous and Racialized groups had a higher seroprevalence rate (5.3% (95% CI 4.4, 6.1)) compared to White donors (2.8 (95% CI 2.5, 3.1)). Those living in materially deprived vs. affluent neighbourhoods had a higher rate of natural infections 4.6% (95% CI 3.5, 5.7) vs 2.7% (95% CI 2.2, 3.2).

March 2021

- Serological testing using the Roche nucleocapsid (N) and the Roche spike (S) total antibody assays allows us to monitor trends in natural infection transmission and vaccine-induced seropositivity.
- Overall, as of March 2021 adjusted seroprevalence by the Roche S assay (proxy for humoral immunity, vaccine or natural infection immunity) was 9.9% (95% CI 9.4, 10.3). The fraction of the population naturally exposed as opposed to developing immunity post-vaccination varied across Canada.
- Adjusted seroprevalence by the Roche S assay alone (N negative, proxy for vaccineinduced immunity) was 6.8% (95% 6.4, 7.16) a significant increase from January.
- Using self-reported vaccine history the Roche S assay alone had a sensitivity of 96.1% to identify vaccination (after 2 weeks)
- Despite broader access to COVID-19 vaccines, seroprevalence by the Roche N assay (proxy for natural infections) continued to increase from January (2.2% (95% 2.1, 2.4) to March (3.3% (95% CI 3.0, 3.5))
- Consistent with previous surveys, donors aged 17-24 years old demonstrated the highest seroprevalence rate (natural infection immunity) 6.37% (5.31, 7.44) compared to other age groups. Rates in this age group were significantly higher in Alberta 14.7% (95% CI 10.8, 18.6) and Manitoba 20.8% (95% CI 12.3, 28.0) than for the full sample.
- The disparities in natural infection immunity seroprevalence rates between Black, Indigenous and Racialized groups and White donors and those living in materially deprived vs. affluent neighbourhoods narrowed for the first time since November 2020 when disparities began to widen.

January 2021 (Roche)

January 1-27, 2021 (n = 33,400 Roche)

- In order to evaluate seroprevalence in the vaccine era, residual blood is now tested using the Roche Elecsys
 [®] Anti-SARS-CoV-2 Spike (S) (semi-quantitative) and N (qualitative) assays. All vaccines will produce antibodies to S but not N, and natural infection will usually produce antibodies to S and N.
- In January 2021, seroprevalence estimates were higher by the Roche S assay (2.78% (95% CI 2.58, 2.97%) compared to either nucleocapsid assays. Seroprevalance by the Roche N assay was 2.24% (95% CI 2.08, 2.41) comparable to the Abbott N (1.99% (95% CI 1.84, 2.15).
- New: 511 (1.5%) of donors self-reported vaccination against COVID-19 in the last 3 months in January 2021.

January 2021

- Seroprevalence in January was 1.99% (95% CI 1.84, 2.15)
- Across Canada seroprevalence remained the highest in Manitoba (3.92% (95% CI 2.92, 4.93)) and lowest in PEI (0%)
- Seroprevalence increased significantly in Ontario (1.16% vs 1.82%) and in Alberta (2.12% to 3.41%) from December 2020 until January 2021
- Consistent with previous surveys, donors aged 17-24 years old the highest seroprevalence rate (3.45% (95% CI 2.87, 4.02).
- Disparities by socioeconomic status and Black, Indigenous and Racialized groups widened. Donors living in the most materially deprived neighbourhoods were nearly 4times more likely to be positive than those living in affluent neighbourhoods (4.04% compared with 1.17%). Black, Indigenous and Racialized groups of donors were two time more likely to be positive than self identified White donors (3.37% compared to 1.66%)
- Detailed comparison with the previous survey (December 2020) is included.

December 2020

December 10-23, 2020 (n = 16,961)

- Seroprevalence in December was 1.37% (95% CI 1.18, 1.56)
- Regional variation: Across Canada seroprevalence remained the highest in Manitoba (3.02% (95% CI 1.75, 4.29) however this was a significant decrease from the last report.
- Donors aged 17-24 years old remained the age group with the highest seroprevalence (2.75% (95% CI 2.01, 3.49)
- Disparities by socioeconomic status widened, donors living in the most materially deprived neighbourhoods were 3-times more likely to be positive than those living in affluent neighbourhoods (2.2% compared with 0.72%)
- New: Longitudinal data on repeat donors illustrating waning S/co ratios over time

- Seroprevalence in November was 1.51% (95% CI 1.31, 1.71)
- Regional variation: Seroprevalence increased mostly in Western Canada. Highest rates were observed in the Prairies; Manitoba's rate increased to 8.56% (95% CI 6.51, 10.62) and Saskatchewan's rate increased to 4.2% (95% CI 2.3, 5.8). There was a slight decrease in Ontario to 0.77% (95% CI 0.56, 0.97%) and PEI remained at 0.
- Donors aged 17-24 years old had the highest seroprevalence rates 2.97% (95% CI 2.20, 3.37%) while donors 40-59 years old 1.09% (95% CI 0.80, 1.38%) had the lowest rates.
- New: Revised time series (Additional data from the correlates of immunity study from April until Aug 31, 2020 are included in this report)
- Comparison of Wave 1 (May-July) to November 2020

October 2020	

October 12-31, 2020 (n = 16,811)

- Seroprevalence increased significantly in October to 0.88% (95% CI 0.73, 1.04) (p=0.04).
- Regional variation: Manitoba's seroprevalence rate increased to 2.96% (95% CI 1.70, 4.23), the highest in Canada. Ontario remained stable at 0.87% (0.65, 1.08)
- New: Heat maps to illustrate inter-provincial variation (by economic regions)
- Disparities widen: Donors that self-identified as White (0.75%; 95% CI 0.61, 0.92) had significantly lower seroprevalence compared to Black, Indigenous and Racialized groups (1.82%; 95% CI 1.21, 2.62)

```
Wave 1
```

May 9, 2020 – July 21, 2020 (n = 74,642)

- Seroprevalence was estimated at 0.70% (95% CI 0.63, 0.77)
- Regional variation: Ontario, 0.88% (95% CI 0.78, 0.99) had the highest seroprevalence, very low seroprevalence in Atlantic provinces.
- Disparities: Donors that self-identified as White (0.66%; 95% CI 0.59, 0.74) had lower seroprevalence compared to Black, Indigenous and Racialized groups (1.09%; 95% CI 0.84, 1.34)

Introduction

SARS-CoV-2 is responsible for the respiratory illness, coronavirus infection disease 2019 (COVID-19). Some people become extremely ill and can die from complications, while others experience mild symptoms or may not be aware of their infection at all. Early in the pandemic (by late March 2020) strict physical distancing measures were implemented. As a result, the first wave of the epidemic in Canada peaked by the end of April 2020 and plateaued during the summer. A resurgence of cases began in late September 2020, peaking in January 2021 (the second wave) which was followed by additional waves. As of November 28, 2023, 4,820,444 cases of COVID-19 had been reported in Canada.

Beginning in January 2021, Alpha (B.1.1.7) began to establish itself as the primary variant of concern (VOC). In late June 2021, Delta (B.1.617.2) was transitioning to be the primary VOC. In mid-December 2021, a new more contagious VOC, Omicron (B.1.1.529) began to establish itself as a primary VOC followed by subvariants. Peak timepoints when each VOC became dominant varied between provinces. By late December 2021 public health testing facilities were overwhelmed by a surge in Omicron variant cases. Omicron infections tended to have milder symptoms and in many jurisdictions testing was increasingly focused on high-risk individuals. Because many people with symptoms were not being tested, as well as those infected but without symptoms, the reported cases underestimate the infection rate. Public health restrictions were largely relaxed by 2022. Surveillance studies that monitor SARS-CoV-2 antibodies are important to understand what proportion of the population have detectable antibodies (seroprevalence) and to monitor trajectories over the course of the pandemic. These data improve mathematical models to predict the course of infection and inform public health policies.

Antibody concentrations typically peak within a month of vaccination and then gradually decrease. Antibody concentrations can be much higher after a subsequent dose of vaccine, or when an infection occurs pre- or post-vaccination. Approximately 91% of the people in Canada aged 18 and older had received a primary vaccine series as of September 10, 2023. Monitoring spike (vaccine) antibody concentrations and the proportion of people with Omicron variant infection provides data for mathematical models to estimate the status of humoral immunity.

In partnership with the COVID-19 Immunity Task Force, Canadian Blood Services is testing residual blood for SARS-CoV-2 antibodies from blood donors. This report tracks SARS-CoV-2 seroprevalence. We present seroprevalence rates based on two Roche total Ig- assays that detect Spike (S) and Nucleocapsid (N) antibodies and monitor the concentration of S antibodies. We assess temporal changes and evaluate differences by geographical regions, age groups, Black, Indigenous and Racialized groups, and socioeconomic status.

Methods

Population

Canadian Blood Services has blood collection sites in all large cities and many smaller urban centres in all provinces except Quebec. People in rural areas may have less opportunity to donate and donations are not collected in the northern territories. Blood donors are reasonably representative of healthy Canadians between the ages of 17 and about 60.

Blood donor eligibility

Before each donation, blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients. There is no evidence that SARS-CoV-2 can be transmitted through blood transfusion, but it is important to ensure other donors and staff are safe while in the blood clinic. Donors are asked if they have had COVID-19 or been in contact with someone who has. Donors are deferred for 2 weeks after symptoms disappear (3 weeks if hospitalized) if they have been in contact with someone who was infected or if they have had the infection. Donors also have their temperature and their hemoglobin level checked before they can donate.

Blood samples

Just before a donor gives their blood donation, several small tubes of blood are collected for infectious disease screening. An extra sample is taken, known as the retention sample, in case extra testing is required (80% of these retention samples are not needed for operational testing). For this study retention samples were aliquoted and frozen at -20°C or colder, starting on May 9, 2020.

Periodicity

All retention samples were tested for SARS-CoV-2 antibodies until July 21, 2020 (Wave 1). From August 2020 until December 2020, only samples from approximately the last two weeks of each month were tested (except samples from August and September which were not tested). In January 2021 a larger sample was tested and in February 2021 samples were not tested. As of March 2021, testing of approximately 2 weeks per month resumed. Beginning in July 2021 the sample size was reduced to include about 300 samples per age/region grouping plus extra repeat tested donors. In December 2021 samples from 2 weeks were tested without sorting in order to be able to report more quickly, and as of January 2022 samples from all weeks of the month were tested. Seroprevalence estimates also include an additional 1,500 residual blood tests from the correlates of immunity study from April 2020 to January 2021. These were tested on a battery of assays (orthogonal testing) including the Abbott IgG Assay.

							20	20				
			March	April	May	June	July	August	September	October	November	December
Seroprevalence ¹					14,541	51,963	21,594			16,811	17,049	16,96
Correlates of												
Immunity Study ²												
						20	21					
	January	February	March	April	May	June	July	August	September	October	November	December
Seroprevalence ¹	34,921		16,873	16,931	17,001	16,884	8,457	9,109	9,363	9,627	9,018	16,810
Correlates of Immunity Study ²												
Ī	2022											
	January	February	March	April	May	June	July	August	September	October	November	December
Seroprevalence ¹	32,505	28,616	26,027	29,787	31,764		31,275	35,165	31,637	31,457	31,080	32,698
Correlates of Immunity Study ²												
Ī						20	23					
	January	February	March	April	May	June	July	August	September	October	November	December
Seroprevalence ¹	32,062	31,755	30,793	31,979	31,711	31,790	31,978	31,776	31,764	31,977		
Correlates of												
Immunity Study ²												

¹ Samples tested with the **Abbott SARS-CoV-2 IgG Assay until January 2021** (residual blood from August 2020, September 2020 and February 2021 are aliquoted but have not been tested). As of January 2021, all samples were tested using the Roche Elecsys ® Anti-SARS-CoV-2 assays (S and N).

² Orthogonal Testing (PI: S. Drews (CIHR 2020) sampling 1,500 samples per month until and including January 2021 (Abbott tested); this study is known as the "Correlates of Immunity Study"

SARS-CoV-2 antibody testing

Two assays were used. The Roche Elecsys ® Anti-SARS-CoV-2 spike semi-<u>quantitative</u> immunoassay detects total antibodies (including IgA, IgM and IgG) to the SARS-CoV-2 spike (S) protein (**Spike antibody**). The Elecsys[®] Anti-SARS-CoV-2 <u>qualitative</u> immunoassay detects total antibodies (including IgA, IgM and IgG) to SARS-CoV-2 using a recombinant protein, nucleocapsid (N) antigen (**Nucleocapsid antibody**). At a concentration of ≥ 0.8 U/mL, the Spike antibody assay was assumed to have sensitivity of 98.8% and specificity of 99.6%. At a concentration of ≥ 1.0 U/mL, the Nucleocapsid antibody assay was assumed to have sensitivity of 99.5% and specificity of 99.8%¹. All testing was conducted at Canadian Blood Services laboratories in Ottawa.

Samples from January 2021 to August 2021 were tested neat and at a 1:10 dilution for Spike antibody, however, by June 2021 many samples were above the maximum detection level when diluted. From September 2021 onwards samples were tested up to a 1:400 dilution.

Serological testing using the Nucleocapsid, and Spike antibody assay allows trends in natural infection transmission and vaccine-induced seropositivity to be monitored². In this report the dual terms Spike antibody/ humoral immunity (by vaccine or natural infection) and Nucleocapsid antibody/proxy for natural infection will be used interchangeably. This is to ease interpretation for readers, with the caveat that these interpretations do not reflect the complexity of adaptive immunity.

Ethical issues

All data were de-identified by the information technology team at Canadian Blood Services by providing a random identification number. Demographic variables were extracted from the Canadian Blood Services donor database (e.g., donation date, birth year, sex, self-reported ethnicity, Forward Sortation Area of residential postal code) and linked to the test data. In the donor pamphlet "What you must know to donate blood" which donors must read before each donation, and in the pamphlet entitled "What happens to your blood donation?" donors were informed that their blood will be tested for routine infectious disease markers and other tests as required. Information about the study was made available on the website in late June 2020 prior to commencing testing. Donors were not informed of their results because confirmatory/supplemental testing was not carried out. This study was approved by the Canadian Blood Services Research Ethics Board.

Data management and analysis

De-identified demographic data were analysed by the Canadian Blood Services Epidemiology & Surveillance Department. Socioeconomic status was estimated by quintiles of the Pampalon Material and Social Deprivation Indices (MSDI). MSDI was derived from 2016 Statistics Canada census, aggregated from postal codes to the dissemination area (DA) level (the smallest geographic unit available in the Canadian census, consisting of 400–700 persons). Because blood donors tend to live in areas close to a blood clinic there will be higher concentrations of donors in certain areas compared with the general population, and lower concentrations in other areas. To make inference to the general population, weighting factors were applied based on the donor's residential Forward Sortation Area (FSA), age group and sex. Data were weighted based on Statistics Canada data (catalogue # 98-400-X2016008). For FSAs with few donors, several FSAs were combined, generally to include at least 500 donors. For data with no FSA recorded or if not in a province where blood is collected (0.2% of samples) weighting was based on FSA of the blood centre.

The seroprevalence was calculated as the number of positive samples divided by all samples tested. Ninety-five percent confidence intervals were calculated based on the Exact method. The adjusted seroprevalence and confidence intervals present the weighted data adjusted for sensitivity and specificity of the assay using the Rogan-Gladen equation³. SARS-CoV-2 seroprevalence was stratified by geography (regions, province and selected metropolitan cities), sex, age groups, self-reported ethnicity, and social and material deprivation indices.

Temporal trends by monthly intervals were evaluated by demographic variables. Statistical comparisons between groups were carried out using logistic regression.

Results

Between October 1 and October 31, 2023, a total of 31,977 unique donors were tested for SARS-CoV-2 antibodies.

Table 1 compares adjusted seroprevalence rates by different assays (**Nucleocapsid and Spike antibody**) by sociodemographic variables for all Canadian provinces (except Quebec and territories). Overall adjusted seroprevalence by Spike antibody (a proxy of humoral immunity) was 100.00% (95% CI 100.00, 100.00%). The adjusted seroprevalence by Nucleocapsid antibody (proxy for natural infection) was 81.62% (95% CI 81.19, 82.06) (please refer to points of interpretation). There was week-to-week variability over the 31-day reporting period from 81.95% (95% CI 81.09, 82.80) to 81.31% (95% CI 80.43, 82.19) to 82.09% (95% CI 81.19, 82.99) to 81.24% (95% CI 80.42, 82.05) (Table A2.1).

Figure 1 illustrates temporal trends of SARS-CoV-2 seroprevalence from April 4, 2020, until October 31, 2023, by monthly intervals. The discontinuation of the line in January 2021 represents the transition from the Abbott assay to the Roche assay. The largest increase in seroprevalence was seen in the Roche anti-S assay, from early-March 2021 to July 2021, mirroring wider first and second dose vaccine roll out. Figure 2 stratifies seroprevalence by regions. Much of the humoral immunity was induced by vaccines (compared to natural infections) across the country. The largest increase in seroprevalence using Roche anti-N began in February 2022 and increased consistent with the Omicron variant wave. Appendix Tables A1.1-A1.6 compare seroprevalence rates by sex, age groups and material deprivation in different regions.

Table 2 compares temporal changes in seroprevalence rates by natural infection (**Nucleocapsid antibody** between September 2023 and October 2023. Overall, the seroprevalence rate for natural infections was similar in October (81.62 (95% CI 81.19, 82.06) compared to September (80.12% ((95% CI 79.68, 80.57)). Donors aged 17-24 years old continued to have the highest seroprevalence rate at 91.79% (95% CI 90.90, 92.67) compared to other age groups.

After vaccination an increase in antibody concentration followed by gradual decline is expected. From September 2021 to October 2023 dilution of high concentration spike antibody samples permitted measurement of antibody concentrations as high as 100,000 U/mL. Figure 3 illustrates distributions of log transformed Spike antibody concentrations from September 2021 to October 2023, stratified by donors seropositive for Spike antibodies only and donors seropositive for Spike antibodies and Nucleocapsid antibodies. Donors with both Spike and Nucleocapsid antibodies tended to have higher concentrations of Spike antibodies than those with only Spike antibodies.

Figure 4 shows regional weekly trends since December 2021 for Nucleocapsid by age group. Figures 5A-H illustrate temporal trends of seroprevalence by Nucleocapsid and Spike antibody results by sociodemographic variables (self-reported ethnicity, age, material deprivation, and social deprivation) from January 2021 to October 2023. Differences in natural infections between White and Black, Indigenous and Racialized groups were seen from January 2021 to October 2023 with Black, Indigenous and Racialized groups having higher natural infection rates. Other sociodemographic variables had significant differences at various months corresponding to the vaccine roll out across Canada with evident trends in certain groups having increased Spike and/or Nucleocapsid antibodies compared to others. Tables A 1.1 to A 1.6 show selected demographic results for October by region (Nucleocapsid and Spike), and additional weekly breakdown of Nucleocapsid antibody results are shown in Tables A 2.1 and A 2.2.

Conclusion

As of October 2023 adjusted seroprevalence by the Spike antibody assay (proxy for humoral immunity) was 100.00% (95% CI 100.00, 100.00%). While humoral immunity was largely driven by vaccination in 2021, most people have now also been naturally exposed (with hybrid immunity) since the arrival of the Omicron variant and subsequent subvariants.

Points for Interpretation

- 1. Blood donors are a healthy sub-set of the adult Canadian population. Important points to keep in mind with regard to representativeness of the sample are:
 - blood donors self-select to donate blood therefore those who choose not to donate blood for whatever reason are not included in the sample.
 - Blood donations are collected from people aged 17 years and older, however there are relatively few donations from elderly donors.
 - Blood donations are collected in larger cities and many smaller urban areas, but people in rural areas may be under-sampled. Canadian Blood Services does not collect blood in the northern territories or the province of Quebec.
- 2. Data were weighted for age, sex, and location to more closely reflect the Canadian population. For example, the Nucleocapsid antibody assay unweighted SARS-CoV-2 seroprevalence for the full sample was 80.57% (95% CI 80.13, 81.00), and after weighting factors applied it was 81.25% (95% CI 80.82, 81.68), then after the weighted seroprevalence was adjusted for sensitivity and specificity, 81.62% (95% 81.19, 82.06). Using the Spike antibody assay, the unweighted SARS-CoV-2 seroprevalence for the full sample was 99.68% (95% CI 99.61, 99.74), and after weighting factors applied it was 99.74% (95% CI 99.67, 99.79), then after the weighted seroprevalence was adjusted for sensitivity and specificity and specificity, 100% (95% CI 100.00, 100.00).
- 3. The sensitivity and specificity of the Roche assays are very good, but it is still possible that some true positives may be missed, and some positive results may be false. Confirmatory testing has not been performed. The seroprevalence was adjusted for sensitivity and specificity using a well-established mathematical formula.

- 4. Different seroprevalence rates by the assays reflect different isotypes being measured. The Roche assay identifies IgA, IgG and IgM antibodies. The Abbott assay measured IgG. Detection of Nucleocapsid antibodies is likely a marker of natural infection while Spike antibodies can be induced by either natural infection or by vaccines.
- 5. Seroprevalence results reflect measurement of humoral immunity. The exact mechanisms of protective immunity against SARS-CoV-2 remains unknown. The protection at particular levels of Spike antibody is unknown. Quantitative results from the Spike antibody assay will be valuable to inform policy regarding booster shots as the science evolves.
- 6. As of September 2021, the dilution for higher concentration (>250 U/mL) was increased from 1:10 to 1:400. This allows antibody concentration to be measured as high as 100,000 U/mL rather than 2,500 U/mL. It is possible that values between 160 and 320 U/mL may be less accurate because they are at the lower end of sensitivity of the assay.
- 7. SARS-CoV-2 antibody signals wane over time.
- 8. Donors may have had multiple infections with SARS-CoV-2.
- 9. Spike antibodies reflect SARS-CoV-2 humoral response. Many Spike antibody positive results are related to vaccination. However, Spike antibody positives are also due to natural infection (with or without N antibodies). Donors with both Spike and Nucleocapsid antibodies are assumed to have had a natural infection; however, they may have also been vaccinated before or after the infection.

Due to a variety of biological factors, donors may have variable antibody responses to different binding sites on the SARS-CoV-2 virus (e.g., Spike, receptor binding domain of Spike, nucleocapsid protein). In October 2023 the two most common positive antibody profile were positive on Spike antibody/positive on Nucleocapsid antibody (80.44%) followed by positive on Spike antibody/negative on Nucleocapsid antibody (19.24%) (see below).

	Nucleocapsid Antibody	Spike Antibody	Total N (%)
	Negative	Negative	62 (0.19)
	Negative	Positive	6,152 (19.24)
	Positive	Negative	41 (0.13)
	Positive	Positive	25,721 (80.44)
Total			31,976

Diagnostic phenotypes in October 2023 (unadjusted)

Note: samples missing anti-N or anti-S results not included in the above

Disclaimer: Canadian Blood Services is providing this report of the study results on an "as is" basis and makes no representations or warranties, express or implied, including with regards to the accuracy, reliability or validity of the information or its fitness for a particular purpose. The use of this report and/or any study results is the responsibility of the user. Canadian Blood

Services assumes no liability resulting from any such use. This report may not be reproduced without permission from Canadian Blood Services.

References

- 1. https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2-s.html
- Whitaker HJ, Elgohari S, Rowe C, Otter AD, Brooks T, Linley E, et al., Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021, Journal of Infection (2021), doi: <u>https://doi.org/10.1016/j.jinf.2021.04.037</u>
- 3. Lang Z, Reiczigel J. Confidence limits for prevalence of disease adjusted for estimated sensitivity and specificity. Preventive Veterinary Medicine. 2014:113;13-2

	Nucleocaps (proxy for n				Spike Antibody Results (proxy for humoral immunity by either natural infection or vaccination)				
	Crude		Adjusted		Crude		Adjusted		
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	
Sex									
Female	12,872	10,511	81.98	81.39, 82.58	12,871	12,848	100.00	100.00, 100.00	
Male	19,105	15,252	81.24	80.62, 81.87	19,105	19,025	100.00	100.00, 100.00	
Age									
17-24	2,491	2,284	91.79	90.90, 92.67	2,491	2,490	100.00	100.00, 100.00	
25-39	7,826	6,648	85.76	84.97, 86.55	7,826	7,820	100.00	100.00, 100.00	
40-59	11,954	9,792	82.51	81.79, 83.23	11,954	11,909	100.00	100.00, 100.00	
60+	9,706	7,039	72.61	71.69, 73.54	9,705	9,654	100.00	100.00, 100.00	
Province									
British Columbia	5,719	4,574	81.51	80.46, 82.56	5,718	5,696	100.00	100.00, 100.00	
Alberta	5,615	4,682	84.86	83.79, 85.92	5,615	5,595	100.00	100.00, 100.00	
Saskatchewan	1,459	1,208	84.16	82.05, 86.27	1,459	1,453	100.00	100.00, 100.00	
Manitoba	1,502	1,236	83.34	81.34, 85.35	1,502	1,497	100.00	100.00, 100.00	
Ontario	15,476	12,282	80.46	79.86, 81.07	15,476	15,430	100.00	100.00, 100.00	
New Brunswick	630	518	82.92	80.37, 85.47	630	629	100.00	100.00, 100.0	
Nova Scotia	975	757	78.09	75.56, 80.62	975	972	100.00	100.00, 100.0	
Prince Edward Island	185	155	84.58	78.93, 90.23	185	185	100.00	98.38, 100.0	
Newfoundland	416	351	85.54	82.66, 88.42	416	416	100.00	100.00, 100.0	
Metro area									
Vancouver	2,949	2,472	84.47	83.18, 85.76	2,949	2,941	100.00	100.00, 100.0	
Calgary	2,209	1,868	85.72	83.89, 87.55	2,209	2,201	100.00	100.00, 100.0	
Edmonton	1,854	1,529	83.97	82.21, 85.72	1,854	1,848	100.00	100.00, 100.0	

Table 1. Comparing SARS-CoV-2 seroprevalence by sociodemographic variables by Nucleocapsid and Spike antibody results in October 2023

1,356	1,026	76.97	74.38, 79.56	1,356	1,354	100.00	100.00, 100.00
5,813	4,768	82.78	81.86, 83.70	5,813	5,798	100.00	100.00, 100.00
959	789	83.57	81.05, 86.09	959	957	100.00	100.00, 100.00
24,920	19,697	80.15	79.65, 80.66	24,919	24,837	100.00	100.00, 100.00
458	384	84.05	80.80, 87.31	458	458	100.00	99.66, 100.00
3,452	2,997	87.54	86.43, 88.65	3,452	3,447	100.00	100.00, 100.00
2,260	1,936	86.20	84.77, 87.63	2,260	2,250	100.00	100.00, 100.00
6,267	5,098	82.46	81.49, 83.43	6,267	6,247	100.00	100.00, 100.00
5,998	4,800	81.33	80.34, 82.33	5,997	5,975	100.00	100.00, 100.00
5,741	4,588	81.01	79.99, 82.03	5,741	5,726	100.00	100.00, 100.00
4,986	3,973	80.67	79.56, 81.77	4,986	4,965	100.00	100.00, 100.00
5,048	4,036	80.79	79.69, 81.90	5,048	5,033	100.00	100.00, 100.00
8,292	6,717	82.27	81.40, 83.13	8,292	8,267	100.00	100.00, 100.00
7,022	5,549	80.26	79.31, 81.20	7,022	6,996	100.00	100.00, 100.00
5,831	4,676	81.28	80.27, 82.29	5,830	5,812	100.00	100.00, 100.00
4,371	3,481	80.81	79.67, 81.96	4,371	4,357	100.00	100.00, 100.00
2,524	2,072	82.03	80.58, 83.48	2,524	2,514	100.00	100.00, 100.00
31,977	25,763	81.62	81.19, 82.06	31,976	31,873	100.00	100.00, 100.00
	5,813 959 24,920 458 3,452 2,260 6,267 5,998 5,741 4,986 5,048 8,292 7,022 5,831 4,371 2,524	5,813 4,768 959 789 24,920 19,697 458 384 3,452 2,997 2,260 1,936 6,267 5,098 5,998 4,800 5,741 4,588 4,986 3,973 5,048 4,036 7,022 5,549 5,831 4,676 4,371 3,481 2,524 2,072	5,813 4,768 82.78 959 789 83.57 24,920 19,697 80.15 458 384 84.05 3,452 2,997 87.54 2,260 1,936 86.20 6,267 5,098 82.46 5,998 4,800 81.33 5,741 4,588 81.01 4,986 3,973 80.67 5,048 4,036 80.79 8,292 6,717 82.27 7,022 5,549 80.26 5,831 4,676 81.28 4,371 3,481 80.81 2,524 2,072 82.03	5,8134,76882.7881.86, 83.7095978983.5781.05, 86.0924,92019,69780.1579.65, 80.6645838484.0580.80, 87.313,4522,99787.5486.43, 88.652,2601,93686.2084.77, 87.636,2675,09882.4681.49, 83.435,9984,80081.3380.34, 82.335,7414,58881.0179.99, 82.034,9863,97380.6779.56, 81.775,0484,03680.7979.69, 81.908,2926,71782.2781.40, 83.137,0225,54980.2679.31, 81.205,8314,67681.2880.27, 82.294,3713,48180.8179.67, 81.962,5242,07282.0380.58, 83.48	5,813 4,768 82.78 81.86, 83.70 5,813 959 789 83.57 81.05, 86.09 959 24,920 19,697 80.15 79.65, 80.66 24,919 458 384 84.05 80.80, 87.31 458 3,452 2,997 87.54 86.43, 88.65 3,452 2,260 1,936 86.20 84.77, 87.63 2,260 6,267 5,098 82.46 81.49, 83.43 6,267 5,998 4,800 81.33 80.34, 82.33 5,997 5,741 4,588 81.01 79.99, 82.03 5,741 4,986 3,973 80.67 79.56, 81.77 4,986 5,048 4,036 80.79 79.69, 81.90 5,048 4,986 3,973 80.26 79.31, 81.20 7,022 5,549 80.26 79.31, 81.20 7,022 5,549 8,292 6,717 82.27 81.40, 83.13 8,292 7,022 5,549 80.26	5,813 4,768 82.78 81.86, 83.70 5,813 5,798 959 789 83.57 81.05, 86.09 959 957 24,920 19,697 80.15 79.65, 80.66 24,919 24,837 458 384 84.05 80.80, 87.31 458 458 3,452 2,997 87.54 86.43, 88.65 3,452 3,447 2,260 1,936 86.20 84.77, 87.63 2,260 2,250 6,267 5,098 82.46 81.49, 83.43 6,267 6,247 5,998 4,800 81.33 80.34, 82.33 5,997 5,975 5,741 4,588 81.01 79.99, 82.03 5,741 5,726 4,986 3,973 80.67 79.56, 81.77 4,986 4,965 5,048 4,036 80.79 79.69, 81.90 5,048 5,033 7,022 5,549 80.26 79.31, 81.20 7,022 6,996 5,831 4,676 81.28 <t< td=""><td>5,813 4,768 82.78 81.86, 83.70 5,813 5,798 100.00 959 789 83.57 81.05, 86.09 959 957 100.00 24,920 19,697 80.15 79.65, 80.66 24,919 24,837 100.00 458 384 84.05 80.80, 87.31 458 458 100.00 3,452 2,997 87.54 86.43, 88.65 3,452 3,447 100.00 2,260 1,936 86.20 84.77, 87.63 2,260 2,250 100.00 6,267 5,098 82.46 81.49, 83.43 6,267 6,247 100.00 5,998 4,800 81.33 80.34, 82.33 5,997 5,975 100.00 5,741 4,588 81.01 79.99, 82.03 5,741 5,726 100.00 4,986 3,973 80.67 79.56, 81.77 4,986 4,965 100.00 5,048 4,036 80.79 79.69, 81.90 5,048 5,033 100.00 5,048 4,036 80.27 79.31, 81.20 7,022 6</td></t<>	5,813 4,768 82.78 81.86, 83.70 5,813 5,798 100.00 959 789 83.57 81.05, 86.09 959 957 100.00 24,920 19,697 80.15 79.65, 80.66 24,919 24,837 100.00 458 384 84.05 80.80, 87.31 458 458 100.00 3,452 2,997 87.54 86.43, 88.65 3,452 3,447 100.00 2,260 1,936 86.20 84.77, 87.63 2,260 2,250 100.00 6,267 5,098 82.46 81.49, 83.43 6,267 6,247 100.00 5,998 4,800 81.33 80.34, 82.33 5,997 5,975 100.00 5,741 4,588 81.01 79.99, 82.03 5,741 5,726 100.00 4,986 3,973 80.67 79.56, 81.77 4,986 4,965 100.00 5,048 4,036 80.79 79.69, 81.90 5,048 5,033 100.00 5,048 4,036 80.27 79.31, 81.20 7,022 6

¹Self reported ethnicity was missing for 887 (2.8%) donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 85.56% (95% CI 83.26, 87.87); and Spike antibody was 100.00% (95% CI 99.75, 100,00).

²Combining all Racialized groups together resulted in adjusted SARS-CoV-2 seroprevalence of 86.78% (95% CI 85.93, 87.62) by the Nucleocapsid antibody assay, and 100.00% (95% CI 100.00, 100.00) by Spike antibody.

³Postal codes were missing for 3,937 (12.3%) of donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 83.99% (95% CI 82.82, 85.15) and Spike antibody was 100.00% (95% CI 100.00, 100.00).

 Table 2. Changes in SARS-CoV-2 seroprevalence by Nucleocapsid Antibody assay (proxy for natural infection) by sociodemographic variables between September and October 2023

	Septemb (cru			otember 2023 (adjusted)	Octobe (cru		-	ctober 2023 (adjusted)	
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	P-Value*
Sex									
Female	12,952	10,334	80.17	79.55, 80.79	12,872	10,511	81.98	81.39, 82.58	0.00
Male	18,812	14,757	80.08	79.44, 80.71	19,105	15,252	81.24	80.62, 81.87	0.01
Age									
17-24	2,066	1,863	90.25	89.29, 91.20	2,491	2,284	91.79	90.90, 92.67	0.02
25-39	7,901	6,645	84.55	83.73, 85.37	7,826	6,648	85.76	84.97, 86.55	0.04
40-59	12,182	9,722	80.52	79.77, 81.27	11,954	9,792	82.51	81.79, 83.23	0.00
60+	9,615	6,861	71.46	70.52, 72.40	9,706	7,039	72.61	71.69, 73.54	0.09
Province									
British Columbia	5,969	4,719	80.50	79.43, 81.57	5,719	4,574	81.51	80.46, 82.56	0.19
Alberta	5,729	4,636	82.54	81.41, 83.66	5,615	4,682	84.86	83.79, 85.92	0.00
Saskatchewan	1,423	1,138	82.05	79.83, 84.26	1,459	1,208	84.16	82.05, 86.27	0.17
Manitoba	1,540	1,260	83.39	81.40, 85.38	1,502	1,236	83.34	81.34, 85.35	0.98
Ontario	14,309	11,197	79.23	78.60, 79.86	15,476	12,282	80.46	79.86, 81.07	0.01
New Brunswick	1,029	799	79.67	76.95, 82.39	630	518	82.92	80.37, 85.47	0.09
Nova Scotia	1,099	807	74.23	71.58, 76.88	975	757	78.09	75.56, 80.62	0.04
Prince Edward Island	203	158	79.34	73.03, 85.64	185	155	84.58	78.93, 90.23	0.23
Newfoundland	463	377	83.31	80.24, 86.37	416	351	85.54	82.66, 88.42	0.30
Metro area									
Vancouver	3,369	2,774	83.56	82.27, 84.85	2,949	2,472	84.47	83.18, 85.76	0.33
Calgary	2,039	1,622	81.84	79.81, 83.87	2,209	1,868	85.72	83.89, 87.55	0.01
Edmonton	1,687	1,369	81.65	79.66, 83.65	1,854	1,529	83.97	82.21, 85.72	0.09
Ottawa	1,257	936	75.85	73.23, 78.48	1,356	1,026	76.97	74.38, 79.56	0.55

Toronto	5,713	4,581	80.95	79.98, 81.91	5,813	4,768	82.78	81.86, 83.70	0.01
Winnipeg	916	749	83.35	80.76, 85.94	959	789	83.57	81.05, 86.09	0.90
Ethnicity ^{1,2}									
White	24,508	18,971	78.42	77.89, 78.94	24,920	19,697	80.15	79.65, 80.66	0.00
Indigenous	448	368	83.52	80.06, 86.98	458	384	84.05	80.80, 87.31	0.83
Asian	3,583	3,032	86.07	84.94, 87.19	3,452	2,997	87.54	86.43, 88.65	0.07
Other Racialized groups	2,391	2,049	86.60	85.24, 87.97	2,260	1,936	86.20	84.77, 87.63	0.69
Social Deprivation ³									
1 (least deprived)	6,025	4,817	81.06	80.06, 82.06	6,267	5,098	82.46	81.49, 83.43	0.05
2	5,951	4,719	80.49	79.47, 81.51	5,998	4,800	81.33	80.34, 82.33	0.25
3	5,424	4,162	77.89	76.78, 79.00	5,741	4,588	81.01	79.99, 82.03	0.00
4	5,160	4,080	80.65	79.55, 81.75	4,986	3,973	80.67	79.56, 81.77	0.98
5 (most deprived)	5,046	3,951	78.93	77.79, 80.06	5,048	4,036	80.79	79.69, 81.90	0.02
Material Deprivation ³									
1 (least deprived)	7,883	6,199	79.45	78.53, 80.37	8,292	6,717	82.27	81.40, 83.13	0.00
2	6,848	5,346	79.39	78.41, 80.37	7,022	5,549	80.26	79.31, 81.20	0.21
3	5,811	4,543	79.53	78.49, 80.57	5,831	4,676	81.28	80.27, 82.29	0.02
4	4,430	3,525	80.53	79.38, 81.67	4,371	3,481	80.81	79.67, 81.96	0.73
5 (most deprived)	2,634	2,116	81.46	80.01, 82.91	2,524	2,072	82.03	80.58, 83.48	0.59
Total	31,764	25,091	80.12	79.68, 80.57	31,977	25,763	81.62	81.19, 82.06	0.00

*P-value reflects the difference between September and October results.

¹ In September, self reported ethnicity was missing for 834 (2.6%) donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 81.70% (95% CI 79.06, 84.33); and Spike antibody was 100.00% (95% CI 99.53, 100,00). In October, self reported ethnicity was missing for 887 (2.8%) donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 85.56% (95% CI 83.26, 87.87); and Spike antibody was 100.00% (95% CI 99.75, 100,00).

² In September, combining all Racialized groups together resulted in adjusted SARS-CoV-2 seroprevalence of 86.09% (95% CI 85.25, 86.94) by the Nucleocapsid antibody assay, and 100.00% (95% CI 100.00, 100.00) by Spike antibody. In October, combining all Racialized groups together resulted in adjusted SARS-CoV-2 seroprevalence of 86.78% (95% CI 85.93, 87.62) by the Nucleocapsid antibody assay, and 100.00% (95% CI 100.00, 100.00) by Spike antibody assay, and 100.00% (95% CI 100.00, 100.00) by Spike antibody.

³ In September, postal codes were missing for 4,158 (13.1%) of donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 82.07% (95% CI 80.87, 83.28) and Spike antibody was 100.00% (95% CI 100.00, 100.00). In October, postal codes were missing for 3,937 (12.3%) of donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 83.99% (95% CI 82.82, 85.15) and Spike antibody was 100.00% (95% CI 100.00, 100.00).




Figure 1. Overall temporal trends of SARS-CoV-2 seroprevalence by monthly intervals from April 2020 - October 2023 (comparing results from Abbott anti-N (until January 2021) followed by seroprevalence estimated by Roche anti-N and Roche anti-S results.

Notes: SARS-CoV-2 seroprevalence rates (95% CI), that have been weighted and adjusted for test characteristics. Data from the CIHR funded study (Correlates of Immunity) from April 9, 2020 - January 31, 2021, have been included.








Figure 2. Regional temporal trends of SARS-CoV-2 seroprevalence monthly from April 2020 – October 2023 (by Abbott anti-N, Roche anti-N and Roche anti-S assays)










Note: SARS-CoV-2 seroprevalence rates (95% CI), that have been weighted and adjusted for test characteristics. Data from the CIHR funded study (Correlates of Immunity) from April 9, 2020 - January 31, 2021, have been included.

Figure 3. Distributions of log transformed Spike antibody concentration results (U/mL) (circle represents the median and the lighter shaded area represents the IQR) in spike antibody seropositive donations from September 2021 – October 2023 stratified by anti-spike positive only and anti-spike and anti-nucleocapsid positive donors.










Figure 4. Regional temporal trends of SARS-CoV-2 Nucleocapsid (infection) seroprevalence by age group weekly from December 2021 – October 2023












Figure 5A. Temporal trends of SARS-CoV-2 seroprevalence by monthly intervals from January 2021 – October 2023 estimated by Nucleocapsid antibody results by ethnicity.






Figure 5B. Temporal trends of SARS-CoV-2 seroprevalence by monthly intervals from January 2021 - October 2023 estimated by Nucleocapsid antibody results by age group.








Figure 5D. Temporal trends of SARS-CoV-2 seroprevalence by monthly intervals from January 2021 – October 2023 estimated by Nucleocapsid antibody results by social deprivation level (1 = least deprived and 5 = most deprived).

		Nucleocapsid (proxy for n	Antibody Reatural infection		Spike Antibody Results (proxy for humoral immunity by either natural infection or vaccination)				
	Cru	de	Adjusted		Cru	de	Adjusted		
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	
Sex									
Female	2,434	1,969	81.96	80.51, 83.41	2,433	2,426	100.00	100.00, 100.00	
Male	3,285	2,605	81.03	79.51, 82.56	3,285	3,270	100.00	100.00, 100.00	
Age									
17-24	333	305	91.77	89.55, 93.99	333	333	100.00	100.00, 100.00	
25-39	1,473	1,277	87.70	85.86, 89.55	1,473	1,470	100.00	100.00, 100.00	
40-59	2,016	1,636	81.98	80.20, 83.75	2,016	2,006	100.00	100.00, 100.00	
60+	1,897	1,356	72.25	70.06, 74.44	1,896	1,887	100.00	100.00, 100.00	
Material Deprivation ¹									
1 (least)	1,364	1,093	82.13	80.04, 84.23	1,364	1,360	100.00	100.00, 100.00	
2	1,386	1,106	80.52	78.32, 82.73	1,386	1,381	100.00	100.00, 100.00	
3	1,105	858	79.94	77.43, 82.44	1,104	1,099	100.00	100.00, 100.00	
4	786	644	83.53	80.84, 86.23	786	785	100.00	100.00, 100.00	
5 (most)	433	341	79.81	75.98, 83.63	433	429	99.71	98.56, 100.00	
Total	5,719	4,574	81.51	80.46, 82.56	5,718	5,696	100.00	100.00, 100.00	

Table A1.1 British Columbia SARS-CoV-2 seroprevalence, Nucleocapsid vs. Spike results in October 2023

¹Postal codes were missing for 645 (11.3%) of donors which could not be included in the quintiles of Material Deprivation. 532/645 were positive by the Nucleocapsid antibody, adjusted SARS-CoV-2 seroprevalence among missing postal codes was 83.61% (95% CI 80.58, 86.65); 642/645 were positive by the Spike antibody, adjusted SARS-CoV-2 seroprevalence was 100% (95% CI 99.78, 100.00).

		Nucleocapsid (proxy for n	Antibody Re atural infection		Spike Antibody Results (proxy for humoral immunity by either natural infection or vaccination)				
	Cru	de	Adjusted		Crude		Adjusted		
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	
Sex									
Female	2,158	1,821	85.16	83.67, 86.65	2,158	2,153	100.00	100.00, 100.00	
Male	3,457	2,861	84.55	83.03, 86.07	3,457	3,442	100.00	100.00, 100.00	
Age									
17-24	461	417	90.65	88.21, 93.09	461	461	100.00	100.00, 100.00	
25-39	1,426	1,233	87.58	85.78, 89.38	1,426	1,426	100.00	100.00, 100.00	
40-59	2,135	1,800	84.65	82.83, 86.46	2,135	2,124	100.00	100.00, 100.00	
60+	1,593	1,232	78.31	75.75, 80.87	1,593	1,584	100.00	100.00, 100.00	
Material Deprivation ¹									
1 (least)	2,095	1,752	85.36	83.61, 87.12	2,095	2,086	100.00	100.00, 100.00	
2	1,139	924	82.34	79.80, 84.88	1,139	1,134	100.00	100.00, 100.00	
3	778	660	85.46	82.68, 88.24	778	778	100.00	100.00, 100.00	
4	468	378	82.40	78.65, 86.14	468	466	100.00	99.25, 100.00	
5 (most)	223	190	84.90	79.65, 90.16	223	222	99.84	98.17, 100.00	
Total	5,615	4,682	84.86	83.79, 85.92	5,615	5,595	100.00	100.00, 100.00	

Table A1.2 Alberta SARS-CoV-2 seroprevalence, Nucleocapsid vs. Spike antibody results in October 2023

¹Postal codes were missing for 912 (16.2%) of donors which could not be included in the quintiles of Material Deprivation. 778/912 were positive by the Nucleocapsid antibody, adjusted SARS-CoV-2 seroprevalence among missing postal codes was 87.53% (95% CI 85.13, 89.92); 909/912 were positive by the Spike antibody, adjusted SARS-CoV-2 seroprevalence was 100% (95% CI 100.00, 100.00).

			I Antibody Re natural infection		Spike Antibody Results (proxy for humoral immunity by either natural infection or vaccination)				
	Cru	de	Adjusted		Cru	de	Adjusted		
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	
Sex									
Female	572	486	85.63	82.78, 88.49	572	570	100.00	99.99, 100.00	
Male	887	722	82.65	79.53, 85.76	887	883	100.00	99.71, 100.00	
Age									
17-24	113	103	91.75	87.26, 96.24	113	112	99.37	97.25, 100.00	
25-39	318	281	87.88	84.20, 91.57	318	318	100.00	99.73, 100.00	
40-59	533	442	83.86	80.15, 87.58	533	530	100.00	99.12, 100.00	
60+	495	382	77.46	72.91, 82.02	495	493	100.00	99.23, 100.00	
Material Deprivation ¹									
1 (least)	480	396	84.07	80.21, 87.92	480	478	100.00	99.46, 100.00	
2	310	251	82.64	77.86, 87.42	310	309	100.00	98.74, 100.00	
3	234	201	86.33	81.56, 91.10	234	233	100.00	98.54, 100.00	
4	117	85	75.79	67.61, 83.97	117	117	99.46	97.01, 100.00	
5 (most)	67	57	86.38	77.49, 95.27	67	67	98.13	93.83, 100.00	
Total	1,459	1,208	84.16	82.05, 86.27	1,459	1,453	100.00	100.00, 100.00	

Table A1.3 Saskatchewan SARS-CoV-2 seroprevalence, Nucleocapsid vs. Spike antibody results in October 2023

¹Postal codes were missing for 251 (17.2%) of donors which could not be included in the quintiles of Material Deprivation 218/251 were positive by the Nucleocapsid antibody, adjusted SARS-CoV-2 seroprevalence among missing postal codes was 87.70% (95% CI 83.15, 92.26); 249/251 were positive by the Spike antibody, adjusted SARS-CoV-2 seroprevalence was 99.41% (95% CI 97.61, 100.00).

			Antibody Res		Spike Antibody Results (proxy for humoral immunity by either natural infection or vaccination)				
	Crude	9	Adjusted		Cru	de	Adjusted		
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	
Sex									
Female	644	539	83.80	81.03, 86.57	644	643	100.00	100.00, 100.00	
Male	858	697	82.87	79.97, 85.77	858	854	100.00	99.85, 100.00	
Age									
17-24	135	124	92.26	88.30, 96.22	135	135	100.00	98.74, 100.00	
25-39	374	330	88.71	85.29, 92.12	374	374	100.00	99.86, 100.00	
40-59	552	455	82.82	79.32, 86.33	552	550	100.00	99.68, 100.00	
60+	441	327	74.72	70.30, 79.14	441	438	99.99	98.89, 100.00	
Material Deprivation ¹									
1 (least)	319	267	85.60	81.44, 89.77	319	319	100.00	99.57, 100.00	
2	265	206	78.65	73.44, 83.86	265	264	100.00	98.83, 100.00	
3	314	256	81.82	77.29, 86.35	314	312	99.82	98.46, 100.00	
4	236	192	82.23	76.97, 87.49	236	234	99.64	97.96, 100.00	
5 (most)	130	115	89.56	84.07, 95.04	130	130	99.70	97.58, 100.00	
Total	1,502	1,236	83.34	81.34, 85.35	1,502	1,497	100.00	100.00, 100.00	

Table A1.4 Manitoba SARS-CoV-2 seroprevalence, Nucleocapsid vs. Spike antibody results in October 2023

¹Postal codes were missing for 238 (15.8%) of donors which could not be included in the quintiles of Material Deprivation; 200/238 were positive by the Nucleocapsid antibody, adjusted SARS-CoV-2 seroprevalence among missing postal codes was 85.12% (95% CI 80.37, 89.87); 238/238 were positive by the Spike antibody, adjusted SARS-CoV-2 seroprevalence was 100.00% (95% CI 99.14, 100.00).

			I Antibody Re natural infection		Spike Antibody Results (proxy for humoral immunity by either natural infection or vaccination)				
_	Crude		Adjusted		Crude		Adjusted		
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	
Sex									
Female	6,129	4,915	80.59	79.74, 81.43	6,129	6,122	100.00	100.00, 100.00	
Male	9,347	7,367	80.33	79.46, 81.21	9,347	9,308	100.00	100.00, 100.00	
Age									
17-24	1,245	1,142	91.74	90.52, 92.95	1,245	1,245	100.00	100.00, 100.00	
25-39	3,788	3,163	84.48	83.33, 85.63	3,788	3,786	100.00	100.00, 100.00	
40-59	5,895	4,766	81.61	80.61, 82.62	5,895	5,876	100.00	100.00, 100.00	
60+	4,548	3,211	70.90	69.61, 72.19	4,548	4,523	100.00	100.00, 100.00	
Material Deprivation ¹									
1 (least)	3,659	2,899	80.19	78.89, 81.49	3,659	3,650	100.00	100.00, 100.00	
2	3,451	2,684	79.37	78.07, 80.68	3,451	3,438	100.00	100.00, 100.00	
3	3,000	2,372	80.31	78.91, 81.70	3,000	2,990	100.00	100.00, 100.00	
4	2,292	1,823	80.95	79.42, 82.47	2,292	2,284	100.00	100.00, 100.00	
5 (most)	1,358	1,112	81.46	79.50, 83.42	1,358	1,354	100.00	100.00, 100.00	
Total	15,476	12,282	80.46	79.86, 81.07	15,476	15,430	100.00	100.00, 100.00	

Table A1.5 Ontario SARS-CoV-2 seroprevalence, Nucleocapsid vs. Spike antibody results in October 2023

¹Postal codes were missing for 1,716 (11.1%) of donors which could not be included in the quintiles of Material Deprivation.1,392/1,716 were positive by the Nucleocapsid antibody, adjusted SARS-CoV-2 seroprevalence among missing postal codes was 81.94% (95% CI 80.20, 83.67); 1,714/1,716 were positive by the Spike antibody, adjusted SARS-CoV-2 seroprevalence was 100.00% (95% CI 100.00, 100.00).

			l Antibody Re natural infection		(proxy for h	numoral immu	Intibody Result Inity by either I Accination)	ts natural infection or
_	Crude		Adjusted		Crude		Adjusted	
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Number Tested	Number Positive	Percent Positive	95% Confidence Interval
Sex								
Female	935	781	83.12	81.12, 85.13	935	934	100.00	100.00, 100.00
Male	1,271	1,000	80.18	77.97, 82.39	1,271	1,268	100.00	100.00, 100.00
Age								
17-24	204	193	94.19	91.38, 96.99	204	204	100.00	99.61, 100.00
25-39	447	364	82.99	79.78, 86.20	447	446	100.00	100.00, 100.00
40-59	823	693	84.87	82.56, 87.19	823	823	100.00	100.00, 100.00
60+	732	531	73.38	70.44, 76.33	732	729	100.00	100.00, 100.00
Material Deprivation ¹								
1 (least)	375	310	85.15	81.78, 88.53	375	374	100.00	99.86, 100.00
2	471	378	81.97	78.74, 85.20	471	470	100.00	100.00, 100.00
3	400	329	82.56	79.12, 86.00	400	400	100.00	100.00, 100.00
4	472	359	75.86	72.29, 79.44	472	471	100.00	99.87, 100.00
5 (most)	313	257	82.32	78.58, 86.07	313	312	100.00	99.74, 100.00
Total	2,206	1,781	81.71	80.22, 83.19	2,206	2,202	100.00	100.00, 100.00

Table A1.6 Atlantic Region SARS-CoV-2 seroprevalence, Nucleocapsid vs. Spike antibody results in October 2023

¹Postal codes were missing for 175 (7.9%) of donors which could not be included in the quintiles of Material Deprivation; 148/175 were positive by the Nucleocapsid antibody, adjusted SARS-CoV-2 seroprevalence among missing postal codes was 86.28% (95% CI 81.54, 91.01); 175/175 were positive by the Spike antibody, adjusted SARS-CoV-2 seroprevalence was 100.00% (95% CI 99.02, 100.00).

		October 1-7	7	October 8-14			c	October 15-2	21	October 22-31		
	Crude	Ad	justed	Crude	Adj	justed	Crude	Crude Adjusted		Crude	Adjusted	
	N Tested (N Positive)	Percent Positive	95% CI	N Tested (N Positive)	Percent Positive	95% CI	N Tested (N Positive)	Percent Positive	95% CI	N Tested (N Positive)	Percent Positive	95% Cl
Sex			-			-		-				
Female	3,276(2,677)	82.58	81.39, 83.77	3,157(2,541)	81.13	79.89, 82.37	2,859(2,362)	82.60	81.37, 83.84	3,580(2,931)	81.70	80.58, 82.82
Male	5,069(4,033)	81.31	80.08, 82.53	4,801(3,832)	81.51	80.26, 82.76	4,221(3,380)	81.53	80.22, 82.85	5,014(4,007)	80.72	79.52, 81.92
Age												
17-24	669(623)	93.48	91.93, 95.02	501(460)	92.88	91.00, 94.76	557(515)	93.19	91.46, 94.92	764(686)	88.67	86.87, 90.48
25-39	2,144(1,829)	86.32	84.81, 87.83	1,916(1,626)	85.78	84.17, 87.40	1,734(1,479)	85.76	84.09, 87.44	2,032(1,714)	85.20	83.66, 86.74
40-59	3,105(2,532)	82.12	80.68, 83.57	3,048(2,469)	82.11	80.68, 83.54	2,614(2,160)	82.80	81.29, 84.32	3,187(2,631)	83.00	81.65, 84.35
60+	2,427(1,726)	71.71	69.77, 73.64	2,493(1,818)	72.68	70.82, 74.53	2,175(1,588)	73.77	71.88, 75.65	2,611(1,907)	72.34	70.60, 74.08
Province												
British Columbia	1,700(1,348)	81.24	79.31, 83.17	1,505(1,205)	81.57	79.48, 83.65	1,177(937)	80.96	78.63, 83.29	1,337(1,084)	82.27	80.15, 84.39
Alberta	1,558(1,298)	84.93	82.88, 86.97	1,288(1,051)	82.78	80.42, 85.13	1,464(1,243)	86.43	84.48, 88.39	1,305(1,090)	84.95	82.76, 87.14
Saskatchewan	296(243)	85.13	80.56, 89.70	315(258)	84.27	79.56, 88.98	449(383)	86.00	82.41, 89.59	399(324)	81.37	77.16, 85.59
Manitoba	341(278)	82.69	78.35, 87.02	394(327)	83.91	80.01, 87.81	384(313)	82.93	78.96, 86.91	383(318)	83.75	79.89, 87.61
Ontario	4,014(3,184)	80.86	79.65, 82.08	3,798(3,007)	80.57	79.32, 81.81	3,265(2,585)	80.49	79.19, 81.78	4,399(3,506)	80.04	78.92, 81.16
New Brunswick	37(25)	65.24	51.62, 78.85	230(189)	83.14	78.92, 87.37	129(109)	85.14	79.84, 90.44	234(195)	84.08	80.03, 88.12
Nova Scotia	216(179)	85.46	80.86, 90.06	272(202)	74.42	69.35, 79.48	147(114)	75.34	68.59, 82.10	340(262)	77.51	73.17, 81.85
Prince Edward Island	46(42)	93.55	85.77, 100.00	52(44)	83.95	73.12, 94.78	8(8)	84.49	63.73, 100.00	79(61)	77.51	67.40, 87.63
Newfoundland	137(113)	84.56	79.35, 89.78	104(90)	87.47	81.83, 93.11	57(50)	87.60	80.64, 94.56	118(98)	84.05	78.56, 89.54
Metro area	, /									`````		·
Vancouver	812(694)	86.18	83.84, 88.52	751(623)	83.26	80.61, 85.90	703(583)	83.69	81.01, 86.37	683(572)	84.56	81.90, 87.21
Calgary	608(525)	88.38	85.09, 91.67	559(465)	83.11	79.28, 86.95	509(429)	85.82	82.05, 89.58	533(449)	85.56	81.82, 89.29
Edmonton	525(420)	81.55	78.01, 85.08	404(327)	82.92	78.97, 86.87	482(419)	88.13	85.12, 91.15	443(363)	83.05	79.45, 86.64
Ottawa	285(208)	73.77	68.07, 79.47	359(277)	78.65	73.72, 83.58	342(265)	79.54	74.59, 84.50	370(276)	75.58	70.41, 80.75

Table A2.1. Weekly SARS-CoV-2 seroprevalence by sociodemographic variables by Nucleocapsid results in October 2023

Toronto	1,711(1,369)	80.87	79.11, 82.64	1,338(1,120)	84.49	82.64, 86.35	1,301(1,073)	82.89	80.95, 84.83	1,463(1,206)	83.36	81.56, 85.15
Winnipeg	209(170)	82.97	77.42, 88.53	273(226)	83.61	78.85, 88.37	225(186)	84.71	79.70, 89.72	252(207)	83.00	78.07, 87.92
Ethnicity ¹												
White	6,363(4,995)	80.10	79.08, 81.12	6,274(4,919)	79.67	78.64, 80.70	5,508(4,409)	80.97	79.92, 82.02	6,775(5,374)	79.97	79.02, 80.92
Indigenous	134(110)	83.66	77.12, 90.20	104(89)	85.05	78.01, 92.10	102(83)	84.73	78.27, 91.18	118(102)	83.15	77.06, 89.23
Asian	990(874)	89.39	87.43, 91.34	815(714)	88.07	85.79, 90.35	778(670)	86.92	84.56, 89.28	869(739)	85.59	83.27, 87.91
Other Racialized groups	634(540)	86.16	83.42, 88.90	554(481)	88.15	85.43, 90.87	500(420)	84.78	81.63, 87.93	572(495)	85.62	82.75, 88.48
Social Deprivation ²												
1 (least deprived)	1,706(1,381)	82.52	80.63, 84.41	1,583(1,278)	81.63	79.66, 83.61	1,345(1,113)	83.99	81.97, 86.01	1,633(1,326)	81.95	80.06, 83.83
2	1,545(1,209)	80.37	78.35, 82.39	1,413(1,131)	82.10	80.05, 84.15	1,372(1,097)	81.07	78.99, 83.15	1,668(1,363)	81.77	79.95, 83.59
3	1,420(1,140)	81.37	79.28, 83.46	1,461(1,168)	81.18	79.11, 83.24	1,258(1,017)	81.62	79.48, 83.77	1,602(1,263)	80.11	78.19, 82.04
4	1,344(1,073)	81.81	79.68, 83.94	1,246(998)	81.11	78.88, 83.34	1,120(885)	80.28	77.98, 82.58	1,276(1,017)	79.50	77.33, 81.68
5 (most deprived)	1,296(1,029)	80.48	78.25, 82.71	1,314(1,038)	79.69	77.46, 81.91	1,059(861)	81.93	79.61, 84.25	1,379(1,108)	81.21	79.12, 83.29
Material Deprivation ²												
1 (least deprived)	2,185(1,734)	81.15	79.44, 82.87	2,131(1,716)	82.12	80.39, 83.85	1,827(1,512)	83.30	81.51, 85.08	2,149(1,755)	82.67	80.99, 84.35
2	1,813(1,431)	81.08	79.20, 82.96	1,786(1,425)	81.36	79.51, 83.22	1,553(1,207)	78.66	76.57, 80.76	1,870(1,486)	79.80	78.04, 81.57
3	1,578(1,266)	81.00	78.99, 83.01	1,393(1,112)	81.17	79.06, 83.29	1,276(1,037)	82.58	80.50, 84.65	1,584(1,261)	80.59	78.66, 82.51
4	1,066(854)	81.28	78.90, 83.66	1,090(856)	79.23	76.86, 81.59	944(755)	82.12	79.78, 84.46	1,271(1,016)	80.78	78.68, 82.89
5 (most deprived)	669(547)	83.28	80.50, 86.07	617(504)	81.30	78.22, 84.39	554(462)	82.95	80.02, 85.89	684(559)	80.70	77.89, 83.52
Total	8,345(6,710)	81.95	81.09, 82.80	7,958(6,373)	81.31	80.43, 82.19	7,080(5,742)	82.09	81.19, 82.99	8,594(6,938)	81.24	80.42, 82.05

¹In Week 1, self reported ethnicity was missing for 224 (2.7%) donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 85.90% (95% CI 81.18, 90.63). In Week 2, self reported ethnicity was missing for 211 (2.7%) donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 82.48% (95% CI 77.18, 87.78). In Week 3, self reported ethnicity was missing for 192 (2.7%) donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 84.60% (95% CI 79.62, 89.58). In Week 4, self reported ethnicity was missing for 260 (3.0%) donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 88.12% (95% CI 84.35, 91.89).

²In Week 1, postal codes were missing for 1,034 (12.4%) of donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 86.32% (95% CI 84.12, 88.51). In Week 2, postal codes were missing for 941 (11.8%) of donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 82.36% (95% CI 79.85, 84.86). In Week 3, postal codes were missing for 926 (13.1%) of donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 84.09% (95% CI 81.69, 86.49). In Week 4, postal codes were missing for 1,036 (12.1%) of donors; Adjusted seroprevalence by the Nucleocapsid antibody assay was 83.20% (95% CI 80.97, 85.44).

		October 1-7		October 8-14 Adjusted			с	October 15-2	1	October 22-31			
		Adjusted					Adjusted			Adjusted			
	N Tested (N Positive)	Percent Positive	95% CI	N Tested (N Positive)	Percent Positive	95% CI	N Tested (N Positive)	Percent Positive	95% CI	N Tested (N Positive)	Percent Positive	95% CI	
British Columbia													
17-24	106(97)	91.81	88.04, 95.57	79(74)	94.44	90.42, 98.45	58(53)	90.49	84.80, 96.18	90(81)	90.34	85.69, 94.99	
25-39	457(406)	89.50	86.40, 92.60	372(321)	87.15	83.41, 90.90	326(279)	86.92	82.90, 90.93	318(271)	86.58	82.48, 90.67	
40-59	578(457)	79.57	76.12, 83.02	556(442)	81.07	77.57, 84.58	383(319)	83.71	79.83, 87.59	499(418)	84.40	81.03, 87.76	
60+	559(388)	71.35	67.23, 75.48	498(368)	73.68	69.41, 77.95	410(286)	70.98	66.31, 75.65	430(314)	73.02	68.50, 77.55	
Total	1,700(1,348)	81.24	79.31, 83.17	1,505(1,205)	81.57	79.48, 83.65	1,177(937)	80.96	78.63, 83.29	1,337(1,084)	82.27	80.15, 84.39	
Alberta													
17-24	105(96)	92.62	88.08, 97.17	92(82)	88.36	82.29, 94.43	136(129)	94.61	91.04, 98.17	128(110)	86.40	81.00, 91.81	
25-39	403(344)	86.18	82.59, 89.77	353(293)	84.68	80.73, 88.62	348(315)	91.03	87.92, 94.14	322(281)	88.53	84.84, 92.21	
40-59	604(517)	85.43	82.05, 88.81	490(399)	82.40	78.34, 86.46	585(489)	84.66	81.26, 88.05	456(395)	85.95	82.18, 89.72	
60+	446(341)	78.66	73.76, 83.56	353(277)	77.77	72.26, 83.28	395(310)	78.17	73.10, 83.24	399(304)	78.55	73.48, 83.62	
Total	1,558(1,298)	84.93	82.88, 86.97	1,288(1,051)	82.78	80.42, 85.13	1,464(1,243)	86.43	84.48, 88.39	1,305(1,090)	84.95	82.76, 87.14	
Saskatchewan													
17-24	24(23)	96.28	89.24, 100.00	16(16)	92.23	81.01, 100.00	31(28)	93.02	85.10, 100.00	42(36)	85.57	76.49, 94.66	
25-39	79(74)	93.28	87.34, 99.22	66(60)	90.40	83.03, 97.78	93(79)	85.48	78.22, 92.75	80(68)	83.84	75.79, 91.89	
40-59	95(76)	82.02	72.72, 91.33	121(103)	85.66	78.18, 93.13	175(151)	86.98	81.13, 92.82	142(112)	79.48	71.52, 87.44	
60+	98(70)	74.35	63.93, 84.78	112(79)	71.58	60.57, 82.59	150(125)	82.31	74.82, 89.79	135(108)	78.56	70.13, 86.98	
Total	296(243)	85.13	80.56, 89.70	315(258)	84.27	79.56, 88.98	449(383)	86.00	82.41, 89.59	399(324)	81.37	77.16, 85.59	
Manitoba													
17-24	29(27)	94.81	87.52, 100.00	27(25)	91.05	81.46, 100.00	33(30)	92.27	84.27, 100.00	46(42)	91.40	84.42, 98.38	
25-39	84(73)	87.55	79.92, 95.19	102(91)	89.31	82.95, 95.67	88(79)	89.93	83.26, 96.61	100(87)	87.94	81.19, 94.69	
40-59	128(101)	79.3	71.53, 87.07	143(118)	82.76	75.83, 89.70	140(116)	83.78	76.99, 90.57	141(120)	85.14	78.60, 91.67	
60+	100(77)	76.81	67.52, 86.11	122(93)	77.77	69.65, 85.88	123(88)	72.98	64.62, 81.35	96(69)	71.26	61.53, 81.00	
Total	341(278)	82.69	78.35, 87.02	394(327)	83.91	80.01, 87.81	384(313)	82.93	78.96, 86.91	383(318)	83.75	79.89, 87.61	
Ontario													
17-24	328(305)	93.21	90.98, 95.44	254(234)	93.87	91.49, 96.25	266(243)	93.11	90.71, 95.50	397(360)	88.43	86.00, 90.85	
25-39	1,042(865)	84.55	82.33, 86.76	905(766)	85.74	83.43, 88.04	806(667)	83.05	80.46, 85.64	1,035(865)	84.44	82.31, 86.57	

Table A2.2. Weekly SARS-CoV-2 seroprevalence by province and age group by Nucleocapsid results in October 2023

40-59	1,551(1,254)	81.97	79.98, 83.97	1,467(1,178)	81.42	79.41, 83.43	1,206(977)	80.84	78.62, 83.06	1,671(1,357)	82.03	80.19, 83.87
60+	1,093(760)	69.70	66.93, 72.47	1,172(829)	70.70	68.07, 73.32	987(698)	73.18	70.59, 75.76	1,296(924)	70.16	67.79, 72.54
Total	4,014(3,184)	80.86	79.65, 82.08	3,798(3,007)	80.57	79.32, 81.81	3,265(2,585)	80.49	79.19, 81.78	4,399(3,506)	80.04	78.92, 81.16
Atlantic Canada												
17-24	77(75)	97.88	94.86, 100.00	33(29)	88.38	78.94, 97.82	33(32)	96.28	90.42, 100.00	61(57)	91.68	85.81, 97.54
25-39	79(67)	86.97	79.96, 93.97	118(95)	81.24	74.80, 87.68	73(60)	83.80	76.47, 91.13	177(142)	82.04	76.71, 87.36
40-59	149(127)	84.99	79.44, 90.53	271(229)	85.37	81.42, 89.33	125(108)	86.96	81.43, 92.49	278(229)	83.36	79.23, 87.50
60+	131(90)	70.50	63.08, 77.93	236(172)	73.81	68.57, 79.04	110(81)	72.13	64.71, 79.55	255(188)	74.93	70.09, 79.77
Total	436(359)	83.9	80.66, 87.13	658(525)	80.72	77.92, 83.51	341(281)	82.35	78.72, 85.98	771(616)	81.03	78.48, 83.58
Total	8,345(6,710)	81.95	81.09, 82.80	7,958(6,373)	81.31	80.43, 82.19	7,080(5,742)	82.09	81.19, 82.99	8,594(6,938)	81.24	80.42, 82.05